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Maternal and foetal characteristics 
affect the levels of the biochemical 
markers in first trimester Down’s 
syndrome screening. Pregnancy as-
sociated plasma protein A is not only 
the best marker to screen for Down’s 
syndrome, but also a significant 
marker for subfertility and adverse 
pregnancy outcomes, such as preterm 
delivery, preeclampsia and small for 
gestational age infants. In this the-
sis, the pregnancy associated plasma 
protein A was examined to elucidate 
how its concentration behaves in 
relation to maternal and gestational 
ages, as well as how these factors 
affect the detection rate of Down’s 
syndrome.   
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ABSTRACT 
 
Maternal and foetal characteristics affect the concentrations of markers used in first 
trimester screening (FTS). Subfertility, manifested as a prolonged waiting time to 
pregnancy (TTP), has been associated with adverse pregnancy outcomes. It has been 
reported that the levels of free beta human chorionic gonadotropin (f -hCG) and 
pregnancy associated plasma protein A (PAPP-A) in the maternal serum deviate 
from the norm in adverse outcomes such as preterm delivery (PD), preeclampsia 
(PE), and small for gestational age (SGA) infants. In addition, the performance of the 
combined first trimester screening (FTS) is known to be superior in older women. 
 The study focused on characteristics affecting the quality of FTS. The screening 
markers for Down’s syndrome (DS) in spontaneous, chromosomally normal 
pregnancies with different TTPs were compared to the results of those for 
pregnancies initiated using in vitro fertilization (IVF). Adverse pregnancy outcomes – 
PD, PE, SGA, and placental abruption (PA) – and their DS screening results were 
examined. In a multicenter study, the detection rates and the number of invasive 
procedures needed to detect a single case of Down's syndrome were analyzed at 
different maternal ages. 
 The main finding was that PAPP-A, which is monitored as part of the screening 
protocol for DS, is the best marker for subfertility and adverse pregnancy outcomes, 
and that its concentration in younger women is significantly lower than is the case in 
older women. The median multiple of median (MOM) values for PAPP-A 
concentrations in spontaneous pregnancies with a TTP over two years and in IVF 
pregnancies were significantly lower than those observed for pregnancies with a TTP 
of less than one year. Because the PAPP-A levels for spontaneous pregnancies with 
TTPs in excess of two years were comparable to those for IVF pregnancies, it seems 
that low PAPP-A concentrations may be related to subfertility rather than the use of 
artificial reproductive technology. The median MOM for PAPP-A was significantly 
lower in pregnancies with PD, PE or SGA, but no difference was found in 
pregnancies with PA. The lower the concentrations of PAPP-A and f -hCG, the 
higher the odds ratios for developing PD or SGA. The mechanism behind PA is 
probably less dependent on the placenta than the decidua, as no difference in 
markers of the FTS was seen. In DS pregnancies, the detection rate when using the 
biochemical markers alone was significantly higher for women who were ≥35 years 
than for younger women. Therefore, for younger women, combined screening 
should be the method of choice. For a fixed false positive rate of five percent, the 
number of invasive procedures needed to detect one case of DS would be higher in 
younger than in older women. 
National Library of Medical Classification: WS 107, WQ 209, WQ 210.5, WH 400, QY 455 
VI 
 
 
Medical Subject Headings: Down Syndrome/diagnosis; Pregnancy Trimester, First; Biological 
Markers; Pregnancy-Associated Plasma Protein-A; Pregnancy Outcome; Prenatal Diagnosis 
 
 
VII 
 
 
Ranta-Ylikulju, Jenni Katriina 
Ensimmäisen raskauskolmanneksen Downin oireyhtymän seulonta – biokemiallisten 
merkkiaineiden rooli, 53 s.  
Itä-Suomen yliopisto, Terveystieteiden tiedekunta, 2012. 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 111. 2012. 
53 s. 
 
ISBN (print): 978-952-61-0769-1 
ISBN (pdf): 978-952-61-0770-7 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
TIIVISTELMÄ 
 
Odottavan äidin, istukan ja sikiön ominaisuudet vaikuttavat ensimmäisen 
raskauskolmanneksen Downin oireyhtymän seulonnan merkkiaineisiin. Seulonnan 
tiedetään havaitsevan paremmin vanhempien kuin nuorempien naisten Down-
raskauksia. Alentunut hedelmällisuus, joka ilmenee pidentyneenä raskauden 
alkamisen viiveenä, on liitetty raskauden poikkeaviin lopputuloksiin, kuten pre-
eklampsiaan eli raskausmyrkytykseen, sikiön kasvuhäiriöön ja ennenaikaiseen 
synnytykseen. Ensimmäisen raskauskolmanneksen seulonnan biokemiallisten 
merkkiaineiden – istukkahormonin vapaan beeta-alayksikön (vapaa -hCG) ja 
raskaudenaikaisen plasmaproteiini A:n (PAPP-A) pitoisuudet on todettu 
epänormaaleiksi näissä komplisoiduissa raskauksissa. 
 Väitöskirjatutkimuksessa tarkasteltiin seulonnan laatuun vaikuttavia tekijöitä. 
Raskausviiveen vaikutusta merkkiaineisiin verrattiin kromosomeiltaan normaaleissa 
spontaanialkuisissa ja keinoalkuisissa raskauksissa. Poikkeavien raskauden 
lopputulosten – myös istukan ennenaikaisen irtoamisen – merkkiaineiden 
pitoisuuksia verrattiin normaaliraskauksiin. Lisäksi seulonnan havaitsemisasteita ja 
tarvittavien kromosomitutkimusten määriä yhden Down-raskauden havaitsemiseksi 
vertailtiin odottavien äitien eri ikäryhmien välillä. 
 PAPP-A:n todettiin olevan paras yksittäinen merkkiaine Down-raskauksien lisäksi 
raskausmyrkytykselle, ennenaikaiselle synnytykselle tai sikiön kasvuhäiriölle. Mitä 
matalammat vapaan -hCG:n ja PAPP-A:n pitosuudet, sitä korkeampi riskisuhde 
ennenaikaiselle synnytykselle ja ikäänsä nähden pienipainoiselle sikiölle. Istukan 
ennenaikaista irtoamista ei voitu ennustaa merkkiaineista. PAPP-A:n pitoisuus oli 
matala myös keinoalkuisissa raskauksissa sekä spontaanialkuisissa raskauksissa, 
joissa oli yli kahden vuoden alkamisviive, verrattuna raskauksiiin, joissa 
alkamisviive oli enintään yhden vuoden. Koska raskaaksi tulemisen viive laskee 
PAPP-A:n pitoisuutta hedelmöityshoitojen tavoin, voi PAPP-A:n lasku liittyä 
alentuneeseen hedelmällisyyteen ennemmin kuin keinoalkuiseen raskauteen. 
Seerumiseulonta toimii parhaiten vanhemmilla naisilla. Nuoremmilla naisilla 
yhdistelmäseulonta on ensisijainen menetelmä. Down-raskauksissa nuorille, <35-
vuotiaille, naisille tarvittiin enemmän kromosomitutkimuksia Down-raskauksien 
löytämiseksi ja havaitsemisaste seerumiseulonnassa oli merkittävästi huonompi kuin 
vanhemmilla, ≥35-vuotiailla, naisilla. 
  
Luokitus: WS 107, WQ 209, WQ 210.5, WH 400, QY 455 
Yleinen Suomalainen asiasanasto: Downin oireyhtymä - - diagnoosi; sikiödiagnostiikka; 
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1 Introduction 
Routine first trimester screening for Down's syndrome is based on knowledge of 
maternal age together with measuring the levels of biochemical markers produced 
by the placenta, and ultrasonic measurements of foetal nuchal translucency (NT). 
Two maternal serum biochemical markers, free -human chorionic gonadotropin (f -
hCG) and pregnancy-associated plasma protein-A (PAPP-A), are used to determine 
whether the placenta is maturing more slowly than would be expected considering 
the gestational age. Although the first trimester screening (FTS) focuses on Down's 
syndrome, it could potentially also be used to identify any form of abnormal 
pregnancy involving an immature placenta, i.e. the other major trisomies (i.e. cases 
where three copies of a give chromosome are present in  a diploid cell) such as 
trisomy 13 and 18 (Spencer and Nicolaides 2002, Wapner et al. 2003, Breathnach et al. 
2007, Kagan et al. 2008), as well as adverse pregnancy outcomes with a normal foetal 
karyotype, such as preterm delivery (PD), preeclampsia (PE), and small for 
gestational age (SGA) foetuses (Smith et al. 2002, Tul et al. 2003, Dugoff et al. 2004, 
Liu et al. 2004, Brameld et al. 2008, Spencer et al. 2008a, Spencer et al. 2008b, Poon et 
al. 2009). It has been shown that low concentrations of PAPP-A are particularly 
common in pregnancies with such outcomes. Abnormal f -hCG and PAPP-A levels 
have also been reported in pregnancies due to in vitro fertilisation (IVF), although the 
frequency of trisomy 21 is virtually unaffected by the use of assisted reproduction 
(Hui et al. 2006, Gjerris et al. 2009). 
 The studies reported in this thesis focused on different aspects of first trimester 
Down’s syndrome screening, and the characteristics that affect the quality of the 
results. In normal singleton pregnancies, we studied the association between the 
waiting time to pregnancy (TTP), measured from the start of attempts to become 
pregnant to the observation of an actual pregnancy, and the combined FTS markers. 
In addition, we examined how the markers of the combined screening behave in 
different adverse outcomes: PD, PE, SGA, and placental abruption (PA). 
Furthermore, we compared the influence of maternal age on the levels of f -hCG and 
PAPP-A in both chromosomally normal and Down’s syndrome pregnancies. 
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2 Review of literature  
2.1 DOWN'S SYNDROME 
Down's syndrome (DS) was named after Langdon Down, a doctor from London who 
first described the condition in 1866 and reported it to be genetic in origin (Down 
1866). The prevalence of Down's syndrome and the various mental disabilities it 
causes in the population is about 0.1 percent (Working group appointed by the 
Finnish Medical Society Duodecim and The Finnish Association of Doctors in 
Developmental Disability 2010). DS is known to be the most important cause of 
mental disability, affecting approximately 10 percent of the mentally disabled 
population (Hagberg and Kyllerman 1983). 
 DS is caused by triploidy of chromosome 21 and is therefore also known as 
trisomy 21. Triploidy normally occurs as a result of incorrect chromosomal 
segregation during mitosis; in 80–90 percent of all cases, the additional chromosome 
21 is maternal and results from nondisjunction, whereby the chromosome pairs fail 
to separate properly, resulting in one cell with 2 copies of chromosome 21 and a 
second with none (Mattei et al. 1980, Mikkelsen 1980, Nicolaidis and Petersen 1998, 
Petersen and Mikkelsen 2000). It is estimated that nondisjunction is typically caused 
by ovarian damage incurred prior to ovulation. Approximately four percent of DS 
cases are believed to arise from translocations between chromosomes 21 and 13, 14, 
or 15. In addition, approximately one percent of DS cases are caused by mosaicism – 
the presence of at least two genetically different kinds of cells in an individual that 
originated from the same fertilised egg, the oozygote. Mosaic aneuploidy, i.e. the 
absence of a specific chromosome or the presence of an extra one in some but not all 
cells of the body, is relatively common in preimplanted embryos (Bielanska et al. 
2002, van Echten-Arends et al. 2011). The extent to which these individuals exhibit 
the symptoms of DS depends on their degree of mosaicism. Hereditary factors are 
not considered to play a major role in determining the likelihood that any given 
pregnancy will result in DS. Instead, it is believed that the likelihood of DS increases 
with maternal age and is also higher for twin pregnancies (Bliumina et al. 1975, Rodis 
et al. 1990), in cases where the mother has sustained ovarian damage prior to puberty 
and menarche, and issues related to folic acid metabolism (Finley 1975, James et al. 
1999). 
 The risk of trisomy 21 increases with increasing maternal age. At week 12 of 
pregnancy, the risk of DS for a 30-year old woman is estimated to be 1:626. 
Approximately one third of foetuses with DS are spontaneously aborted in the early 
stages of pregnancy, and so the risk at birth is approximately 1:800. The equivalent 
risks in a 40-year old woman are 1:68 and 1:97, respectively (Snijders et al. 1999). In 
the Finnish population, the risk of recurrent DS pregnancy is estimated to be 
approximately two percent in women aged <35 years, and approximately eight 
percent in women aged ≥35 years (Leskinen et al. 1996). 
 Numerous health problems are associated with DS. Defects in mental abilities, 
especially relating to development of speech, as well as mental retardation, are 
common. Individuals with DS are susceptible to infections and leukemia. Anomalies 
of the digestive tract and cardiovascular system are common, and congenital heart 
defects occur in 40–50 percent of DS individuals. Atresias – also known as congenital 
obturations – are also common and often require early surgical repair. In addition, 
problems with eyesight and hearing are common (Roizen et al. 1993). There are a 
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characteristic set of facial features associated with DS and affected individuals tend 
to be shorter than the population average. In addition, the head circumference of DS 
children is usually smaller than average. Individuals with DS have a tendency to 
become overweight, and the functioning of their gastrointestinal system is slow. 
Obstipation and gallstones are both common from childhood onwards (Buchin et al. 
1986). The risks of hypothyroidism and diabetes are high (Loudon et al. 1985). Men 
with DS are almost invariably infertile, but women are not. In addition to somatic 
problems, comorbidity with psychiatric diseases is common. Dementia usually 
affects individuals with DS earlier than the rest of the population, often becoming 
apparent in the early 60’s (Lai et al. 1989). Approximately 10 percent of DS 
individuals are at least somewhat autistic, and depression is twice as common in DS 
individuals compared to groups with different mental disabilities (Collacott et al. 
1992). The life expectancy of individuals with DS is approximately 50–65 years. 
Despite these difficulties, most people with DS live happy lives, especially if they are 
given enough support to live independently. 
 
2.2 ADVERSE OUTCOMES IN CHROMOSOMALLY NORMAL 
PREGNANCIES 
Adverse pregnancy outcomes are those that are associated with elevated mortality, a 
need for extensive prenatal, perinatal and postnatal follow-up, and subsequent needs 
for intensive care of either or both of the pregnant woman and the neonate. Adverse 
pregnancy outcomes often have negative effects on the child that persist for many 
years (Yanney and Marlow 2004, Marlow et al. 2005, Duley 2009). In addition to their 
impact on quality of life, adverse pregnancy outcomes are associated with increased 
direct and indirect costs for the health care system (Cuevas et al. 2005, Desgualdo et 
al. 2011, Bérard et al. 2012). 
 In this work, we focused on the following major adverse pregnancy outcomes: 
placental abruption (PA), preterm delivery (PD), preeclampsia (PE), and small for 
gestational age (SGA) infants. Whilst it is known that chronic maternal diseases such 
as hypertension increase the risk of an adverse pregnancy outcome (Mavalankar et 
al. 1992, Catov et al. 2008), the vast majority of such outcomes occur in healthy 
pregnant women with no known chronic diseases (Toivonen et al. 2002). Other 
adverse outcomes were excluded, including the effects of alcohol or drug exposure 
during pregnancy. In Finland, approximately 500 children (0.8 percent of all 
newborns) that have been adversely affected by alcohol are born each year, and these 
infants may suffer from problems such as neurological development disorders, 
impaired general and skeletal growth, and changes in hormone secretion (van 
Faassen and Niemelä 2011). 
2.2.1 Placental abruption 
Abruption of the placenta is defined as a partial or complete premature 
disengagement of the placenta between gestational weeks 22–37. PA occurs in 
approximately 0.4–1.2 percent of deliveries (Kåregård and Gennser 1986, Saftlas et al. 
1991, Ananth and Wilcox 2001) and is a major risk for foetal and neonatal mortality 
(Oyelese and Ananth 2006, Pariente et al. 2011, Tikkanen 2011). It also endanger the 
health of the pregnant woman because it causes hypovolemic shock due to massive 
bleeding and disseminated intravascular coagulopathy. Amniotic embolus may also 
be a fatal complication. The diagnosis of PA is often clinical in the most severe cases, 
its onset is very rapid, and PA may cause an obstetric emergency involving bleeding, 
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hypovolemia, painful and long-lasting contractions of the uterus, foetal asphyxia, 
and changes in the cardiotocography. In oligosymptomatic cases with less bleeding, 
ultrasound is used to detect intrauterine bleeding or hematoma. The treatment of PA 
is based on hypovolemic shock repair, artificial rupture of the membranes in order to 
reduce the uterine pressure, emergency Caesarean section, treatment of disseminated 
intravascular coagulopathy by rapid evacuation of the uterine cavity, and 
replacement of blood products (Montagnana et al. 2010). 
 The actual abruption is caused by decidual vascular damage. The causes of PA are 
multifactorial; it is indicated by placental and intrauterine disturbances, such as early 
and abnormal vascularisation (Dommisse and Tiltman, 1992), inflammation 
(Steinborn et al. 2004), PE (Wang and Yang 2010), maternal hypertension, excess 
alcohol consumption during pregnancy (Leunen et al. 2003), intrauterine infection, 
premature rupture of membranes, polyhydramnion, trauma to the uterus (Melamed 
et al. 2011), prior uterine curettage, and advanced maternal age. It can also be 
induced by the birth of the A twin in cases of multiple pregnancy, which causes a 
sudden decrease in uterine volume. Some familial clustering has also been observed 
(Toivonen et al. 2004). Despite risk factor mapping, the occurrence of PA is mostly 
unpredictable, and there is no efficient method for its prevention. 
2.2.2 Preterm delivery 
PD or preterm birth is defined as birth at any point before the end of the 37th week of 
pregnancy. According to the Finnish Register of births, 5.9 percent of living 
newborns were delivered prematurely between 1999 and 2009 (Vuori and Gissler 
2011). A World Health Organization (WHO) working group estimated that the 
percentage of PD in developed countries is five to seven percent, but that it is 
substantially higher in developing countries, leading to an incidence of 9.6 percent 
worldwide (Beck et al. 2009). Risk factors include prior PD or having given birth to a 
low birth weight (LBW) infant, prior foetal intrauterine death, prior induced 
abortions or miscarriages (Harlap and Davies 1975), chronic maternal illnesses such 
as hypertension (Czeizel and Bánhidy 2011), multiple pregnancy (Koivisto et al. 1975, 
Roberts et al. 1990), bleeding during the pregnancy, PA, placenta praevia, PE, 
intrauterine growth restriction (IUGR) (Horta et al. 1997, Favilli et al. 2011), obstetric 
cholestasis, social problems during the pregnancy, alcoholism, smoking, 
primigravida, and very young or very advanced maternal age (Altmann and Kucera 
1975, Hiersche et al. 1975). PD is therefore often associated with other major adverse 
pregnancy outcomes and consequences for SGA newborns. Because PD is 
multifactorial, it is often impossible to predict its occurrence. It is therefore best 
treated preventatively, by taking steps to ensure a pregnancy of the normal duration 
(Saling et al. 2001). 
2.2.3 Preeclampsia 
A woman is defined as suffering from PE if her blood pressure is measured to be 
above >140/90 mmHg on multiple occasions, with proteinuria of >0.3 g/day 
(American Congress of Obstetricians and Gynecologists 2002). According to WHO, 
PE occurs in approximately three percent of pregnant women in developing 
countries, and approximately one percent in developed countries (Dolea and 
AbouZhar 2003). Its onset usually occurs during weeks 32–36 of the pregnancy. PE is 
considered to be a preliminary stage of eclampsia, and any convulsions it causes are 
regarded as actual eclamptic seizures.  Severe PE can cause swelling, headaches, 
epigastric pain, and oliguria i.e. reduced diuresis. Approximately 20 percent of 
women with severe PE develop HELLP (i.e. hemolysis, elevated liver enzymes, low 
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platelets) syndrome (Sibai et al. 1993), in which the normal coagulation system is 
disturbed (Weinstein 1982). 
 The aetiology of PE is currently unknown; vasoconstriction and thrombocyte 
aggregation are involved (Maynard et al. 2008), and the early placental 
vascularisation is incomplete. The levels of angiogenic factors such as vascular 
endothelial growth factor and placental growth factor are reduced (Clark et al. 1998, 
Lim et al. 2008,), while levels of antiangiogenic factors such as the soluble vascular 
endothelial growth factor receptor (Clark et al. 1998, Vaisbuch et al. 2011) and the 
soluble fms-like tyrosine kinase are increased (Lim et al. 2008, Woolcock et al. 2008). 
Known risk factors include primigravida, multiple pregnancy, maternal obesity, 
familial clustering (Mandal et al. 2011) and polycystic ovarian syndrome (Kjerulff et 
al. 2011). By reducing placental blood flow, PE impairs foetal growth, causes 
asphyxia, and may increase the perinatal death rate (Andersch et al. 1984). Daily 
treatment with low doses of acetylsalicylic acid starting in the early stages of 
pregnancy has been reported to reduce the incidence of PE (Bujold et al. 2009, WHO 
2011), although this finding is somewhat controversial and only supports the use of 
aspirin in high-risk populations (Rossi and Mullin 2011, Trivedi 2011). PE screening 
is performed as a matter of routine in maternity care units, and when diagnosed, the 
aim of the treatment is to prevent the condition from getting worse by administering 
medication to reduce blood pressure and imposing bed rest. Patients with PE face an 
increased risk of cardiovascular diseases later on life (Smith et al. 2001, Pell et al. 
2004). 
2.2.4 Small for gestational age infants 
SGA infants are smaller in size for their sex and gestational age than normal infants, 
i.e. their sex- and age-adjusted birth weight puts them into the 5th or 10th percentile 
for all infants or is more than two standard deviations below the mean, depending 
on the definition being used. Some small infants may be constitutionally small – if 
the mother is small, her child being small is probably benign. However, if the infant 
has been subject to IUGR during the pregnancy, they are almost certain to be SGA. 
SGA indicates that the foetus was unable to achieve its complete potential genetic 
growth. By definition, the term SGA takes the infant’s gestational age into account, 
whereas LBW is defined in absolute terms as a birth weight below 2500 grams, 
regardless of the stage of gestation at birth. Approximately 1/3 of infants with LBW 
are also SGA. 
 There are both maternal and placental risk factors for SGA; in both cases, they are 
generally caused by deficiencies in nutrition or circulation. Specific risk factors 
include famine or malnutrition, excessive physical exertion during pregnancy, 
alcohol consumption, medication (Ostesen 1994, Nakhai-Pour et al. 2010, Galbally et 
al. 2011), smoking, and insufficient vitamin D supplementation (Bodnar et al. 2010). 
Certain medical conditions also present risk factors, including placenta 
circumvallata, placental hemangiomas, bleeding during pregnancy, multiple 
pregnancy, foeto-foetal transfusion syndrome, infections during pregnancy, low 
weight gain during pregnancy, low oxygen supply (which is a consequence of PE), 
hypertension, vascular collagenous diseases, metabolic diseases (Diderholm 2009), 
diabetes, and placental infarctions. Finally, certain genetic abnormalities increase the 
risk of SGA, including trisomies, Turner's syndrome, deletions, placental mosaicism, 
and other anomalies (Wilkins-Haug et al. 1995). Both IUGR and SGA are screened for 
during pregnancy by monitoring maternal weight gain and foetal palpation, by 
measuring the abdominal circumference and the height of the uterus, and by 
ultrasonography. The treatment of SGA depends on the severity of the situation and 
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whether the IUGR is increasing. If necessary, the pregnancy is terminated by 
inducing delivery or Caesarean section, provided that the risks of immaturity are 
considered less severe than those presented by continuing the pregnancy. 
2.3 SCREENING FOR DOWN'S SYNDROME 
2.3.1 Preconditions of Down's syndrome screening 
According to WHO, screening for a disease or condition should be performed if the 
following criteria are satisfied: 1) the screened condition should be a major health 
problem, 2) there should be an acceptable treatment if the condition is diagnosed, as 
well as 3) facilities for diagnosis and treatment, 4) the condition should have a 
recognizable latent stage or early symptomatic stage, 5) there should be suitable 
screening test for the disease that has few false positives (i.e. the test should be 
specific) and few false negatives (i.e. the test should be sensitive), 6) the screening 
test should be acceptable to the population, 7) the natural history of the condition 
should be adequately understood, 8) there should be an agreement regarding which 
patients should be treated, 9) the cost, including diagnosis and subsequent treatment, 
should be economically balanced in relation to expenditure on medical care as a 
whole, and 10) case finding should be a continuous process (WHO 1968). 
 A report produced by the Finnish Office for Health Technology Assessment 
(FinOhta) in 2005 discussed the objectives of screening for chromosomal 
abnormalities, and posed questions that should be considered when offering a 
screening. Specifically, it asked whether it is justifiable to screen for an abnormality 
that can not be treated and will often lead to miscarriage, or intrauterine or neonatal 
death, and if the screening is considered necessary, how big should the risk of the 
abnormality be in order to consider the screening and invasive testing reasonable in 
relation to the increased risk of miscarriage caused by the invasive tests (Autti-Rämö 
et al. 2005). 
 The different methods used in foetal screening differ from one-another in terms of 
the gestational age at which they can be applied and the nature of the screened 
condition. There is no optimal point in time for all conditions to be screened. If the 
objective of the screening campaign is to identify pregnancies with major 
chromosomal abnormalities and the foetal chromosomes are to be tested, with the 
possibility that the pregnancy may be terminated on the basis of the results, the 
screening must be performed at a sufficiently early stage to enable karyotyping to be 
completed before it becomes unlawful to perform an abortion (The law on pregnancy 
abortion 1970, National Supervisory Authority for Health and Welfare 2012). 
 Because screening of foetal chromosomal abnormalities and anomalies is always 
fraught with ethical issues, screening should be performed at the earliest possible 
stage using the most precise method available. This maximises the amount of time 
available for the pregnant woman and her family to discuss their participation in 
potentially invasive procedures and the continuation or termination of the 
pregnancy. When a pregnant woman participates in screening, she must be informed 
that if invasive testing will be needed to diagnose the condition and to investigate the 
foetal chromosome, invasive tests carry a risk of miscarriage (Autti-Rämö et al. 2005).  
 According to our estimates, approximately 70 percent of pregnant Finnish women 
underwent FTS in 2002–2008. Although foetal screening has become more popular 
over time, the prevalence of births in which the neonate has DS has increased in line 
with the increase in the mean maternal age of the pregnant population. In 2005, the 
mean maternal age in women giving birth was 30.0 years, and 71 children with DS 
were born (12.3/10 000 births). In 2008, 81 children with DS were born (13.6/10 000 
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births) and the mean maternal age was 30.1 years. The mean prevalence of DS at 
birth was thus approximately 1:813 in 2005, and 1:735 in 2008 (Ritvanen and Sirkiä 
2011).  In Finland, around 60 000 births occur every year (Vuori and Gissler 2011). 
With the present screening routine, approximately 75 babies with DS are born each 
year; it is estimated that without this screening program, there would be 
approximately 145 DS births each year (Ryynänen et al. 2004). Consequently, the 
prevalence of DS in newborns between 1993 and 2006 was 1:800, whereas its 
prevalence without routine screening would be approximately 1:600 (Ritvanen and 
Sirkiä 2011). 
2.3.2 History of Down's syndrome screening in Finland 
In the early 20th century it was known that DS was most common in elderly pregnant 
women, and maternal age was the first metric used in screening for DS. Following 
the discovery of karyotyping techniques, it was shown in 1959 that DS was caused by 
triploidy in chromosome 21 (Lejeune et al. 1959). Diagnosis during pregnancy 
became possible at the end of 1960’s, when cells collected from the amniotic fluid 
could be grown for determination of the chromosomes (Steele and Breg 1966). In 
Finland, amniotic fluid sampling (AFS) or chorionic villous sampling (CVS) was 
offered to pregnant women aged over 35–37 years during the 1970’s. While the mean 
age of pregnant women has risen over the last few decades, screening merely based 
on age does not satisfy the established criteria for screening, since less than half of DS 
pregnancies occur in women aged 35 years or more (Ritvanen and Sirkiä 2011). 
 The Finnish National Health Law of 1972 revised the regulations concerning 
maternal care and follow-up during pregnancy but does not discuss foetal screening 
(Finnish acts and decrees, 1972). In the 1970´s, ultrasound examinations during the 
second trimester were introduced to screen for structural abnormalities. Foetal 
screening based on second trimester serum markers was generalized in a stepwise 
fashion during the 1980´s. During weeks 15–17, the concentrations of alpha-1-
fetoprotein (AFP) secreted by foetal liver and human chorionic gonadotropin (hCG) 
secreted by placental trophoblasts were measured from maternal serum samples 
using immunofluorescence (Grenier et al. 1978, Stenman et al. 1983). In the mid 
1990’s, 93 percent of municipalities offered structural ultrasound examinations and 
second trimester serum screening was offered in approximately 70 percent of 
municipalities (Asmala 1995). 
 AFP and hCG were originally both identified as markers of impaired foetal 
development (Mishell and Davajan 1966, Seppälä et al. 1973). In a mother with a DS 
pregnancy, the concentration of AFP is low (Merkatz et al. 1984), while the 
concentration of hCG is high for the foetus’ gestational age (Cuckle et al. 1984, Bogart 
et al. 1987). Second trimester serum screening detects approximately 60 percent of all 
pregnancies with trisomy 21 (Haddow et al. 1992), and six to eight percent of 
screened women are recommended for invasive testing with AFS or CVS. Second 
trimester screening is not specific for DS, but the advantage of detecting elevated 
AFP concentrations is that it also makes it possible to identify foetuses with some 
other major anomalies such as congenital nefrosis (Heinonen et al. 1996a) and spina 
bifida, i.e. a disturbance in the normal closing of the neural tube (Wald et al. 1977, 
Norgaard-Pedersen et al. 1985). The disadvantage of second trimester screening is 
that it is performed at a relatively late stage in the pregnancy; if the results of the 
screening indicate a high risk of an adverse outcome and invasive testing is needed 
to verify the chromosome, the pregnancy will be in its 18th or 19th week when the 
termination is performed. By this point the pregnant woman will be able to sense the 
foetal movements, and the termination becomes very demanding in both mental and 
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physical terms. In addition, while second trimester screening works satisfactory in 
women aged >35 years, its performance is poor for younger women (Spencer 1999, 
Beaman and Goldie 2001). 
 Increased nuchal translucency (NT), i.e. a swelling in the back of the foetus’ neck, 
was discovered to be an ultrasound marker for chromosomal disorders in the early 
1990’s; it becomes apparent between the 10th and 14th weeks of gestation (Nicolaides 
et al. 1992, Pandya et al. 1994). Traditionally, the practice was that if the NT was 
more than three millimetres in length, AFS or CVS was offered. It was soon found, 
however, that not all foetuses with trisomy 21 had such large NTs (Bewley et al. 1995, 
Hafner et al. 1995). NTs more than three mm are observed in approximately one 
percent of all pregnancies, and this percent includes 50-70 percent of all instances of 
trisomy 21, regardless of maternal age (Taipale et al. 1997, Pajkrt et al. 1998). Because 
of the NT scan’s low cost and low screening positive rate, it became the only 
screening method used by many public health care services in the late 1990’s. 
However, despite the introduction of this test, the prevalence of DS in newborns 
increased – between 1996 and 1999, DS was observed in 10.0–11.3 / 10 000 newborns, 
whereas in 2001 it was 14.2 / 10 000 (Ritvanen and Sirkiä 2011). By combining the NT 
measurement with data on maternal age, and gestational age as determined by the 
crown-rump length (CRL), 54 to 77 percent of all DS pregnancies could be detected  
(de Graaf et al. 1999, Bindra et al. 2002, Crossley et al. 2002) with a false positive rate 
(FPR) of five percent. This demonstrates that optimally carried out measurements 
can provide results that are about as good as those obtained using second trimester 
serum screening. 
 PAPP-A was first identified in the 1970’s (Lin et al. 1974), and was subsequently 
shown to be secreted by placental trophoblasts (Chemnitz et al. 1984). Furthermore, 
PAPP-A was found to be representative in the first trimester only (Bersinger and 
Klopper 1984). In early 1990’s, a connection between DS and low PAPP-A levels was 
identified (Cuckle et al. 1992, Brambati et al. 1993). As hCG and f -hCG had both 
been found earlier to be representative in the first and second trimesters (Krantz et al. 
1996, Alfthan et al. 1988), first trimester serum screening with f -hCG and PAPP-A 
was estimated to be as sensitive as second trimester triple screening with AFP, hCG 
and unconjugated estriol, uE3 (Wald et al. 1988, Krantz et al. 1996, Wald et al. 1996a). 
Estriol is an estrogen hormone and a metabolite of estradiol. It is mainly secreted 
from the placenta, and is therefore most abundant during pregnancy. In a DS 
pregnancy, the concentration of estriol is lower than in a normal pregnancy (Canick 
et al. 1988, Haddow et al. 1990, Cuckle and van Lith 1999).  
 The detection rate (DR) of the first trimester biochemical markers has been 
reported to range from 55 to 83 percent with an FPR of five percent (Brambati et al. 
1994, Krantz et al. 1996, Cuckle and van Lith 1999, de Graaf et al. 1999, Bindra et al. 
2002, Wald et al. 2003, Kagan et al. 2009). F -hCG testing alone detects 28 percent 
(Wald et al. 2003), and PAPP-A testing alone identifies 44–60 percent of DS 
pregnancies (Brambati et al. 1993, Wald et al. 2003). 
 The predecessor of the Finnish National Institute for Health and Welfare (THL), 
the Centre for Research and Development of Welfare and Health (STAKES), issued a 
recommendation on foetal screening in 1999 (Viisainen 1999). It was suggested that 
voluntary screening should be offered to all pregnant women in the public health 
care system. Structural ultrasound examination was recommended during weeks 16–
19 and it was stated that screening for DS should be conducted by means of 
ultrasound scanning during week 13 or 14 of the pregnancy or by second trimester 
serum sampling during weeks 15–16. For women aged >39 years, it was suggested 
that CVS should be offered during weeks 11–12 or AFS during weeks 14–15. In 
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women aged <35 years, CVS or AFS was recommended for the screening positives 
only. For women aged 36–38 years, either method could be used. In addition to early 
ultrasound screening or second trimester serum screening, a second trimester 
ultrasound could be performed during weeks 18–20 to identify structural 
abnormalities that would require close monitoring during the pregnancy, such as 
neural tube defects or renal, urinary, and cardiac anomalies. 
 According to a survey in 2002 (Terho 2002, Autti-Rämö et al. 2005), the 
recommendation given in 1999 was not carefully followed in most municipalities. 
About 90 percent of municipalities offered some sort of screening, but practices 
varied widely. Responses to a survey of hospitals indicated that the NT scan was the 
most commonly offered test, being available in 75 percent of all hospitals. First 
trimester serum screening was available in approximately 15 percent, and the 
combined FTS was offered by only 10 percent of hospitals. 
 Serum marker levels and results of the NT scan are independent of one-another in 
both normal and DS pregnancies. Using both tests in tandem therefore provides a 
more powerful and accurate risk assessment than can be achieved using either alone. 
The combined FTS method has a FPR of five percent and its sensitivity ranges from 
79 to 92 percent, depending on the fluid tested – whole blood, plasma or serum 
(Bindra et al. 2002, Malone et al. 2005, Kagan et al. 2008, Kagan et al. 2009) – as well 
as the maternal age (Orlandi et al. 1997, Krantz et al. 2000, Wapner et al. 2003). 
 It was shown that the sensitivity and specificity of second trimester screening 
could be improved by monitoring a fourth serum marker, inhibin A, in addition to 
the traditional markers AFP and f -hCG, and the newer marker uE3 (Aitken et al. 
1996, Wald et al. 1996b, Cuckle 2000). Inhibin A is a glycoprotein hormone that 
develops in the gonads and inhibits sex hormone secretion. It is found in the 
placenta, and may affect the production of hCG in trophoblasts (Steele et al. 1993). In 
DS pregnancies, the concentration of Inhibin A is higher than usual (Aitken et al. 
1996). Using this quadruple screen, up to 81 percent of pregnancies with trisomy 21 
can be detected with a five percent FPR (Gilbert et al. 2001, Wald et al. 2003, Malone 
et al. 2005). This extended second trimester screen thus performs about as well as the 
combined FTS. 
 Ethical factors, practicality, and economic costs should be considered when 
planning, performing, and developing screens. If DS can be screened during the first 
trimester, second trimester screening seems obsolete. Between 85 and 90 percent of 
all foetal aneuploidies can be detected in the first trimester. Following first trimester 
screening, second trimester serum screening using AFP and f -hCG can only identify 
six percent of the missing 10 to 15 percent of all DS pregnancies. In addition, the 
number of invasive procedures increases at later stages. It is therefore best to screen 
as early as possible. 
 A two-phase integrated screening using both the combined FTS and second 
trimester quadruple screening would be as sensitive as the combined FTS but would 
have an FPR of only two percent. A detection rate of 85 percent would be achieved at 
a FPR of 1.2 percent (Wald et al. 2003); equivalently, up to 96 percent of DS 
pregnancies would be identified with an FPR of five percent (Wald et al. 2003, 
Malone et al. 2005). In 2001–2005, large multicenter studies were published 
comparing different methods of foetal screening. Integrated screening was found to 
be the most sensitive, most specific and the safest of the tested methods in terms of 
the risk of miscarriage, but it was also the most expensive and was considered 
unsuitable for routine use (Gilbert et al. 2001). However, although integrated 
screening was the most expensive screening method, it was found to be the most 
cost-effective in terms of determining when invasive tests would be needed (Wald et 
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al. 2003). Screening based on maternal age and first or second trimester serum 
screening alone were found to be the least sensitive and specific methods, resulting 
in the greatest numbers of miscarriages; as such they were the least cost-efficient of 
the tested techniques (Gilbert et al. 2001). It was concluded that the best methods 
overall were integrated screening and the combined FTS with NT measurement 
when performed properly (Gilbert et al. 2001, Malone et al. 2005). In its 2005 report, 
FinOhta stated that the practical complexity and high cost of the integrated screening 
method makes it inappropriate for routine use (Autti-Rämö et al. 2005). Table 1 
compares the different screening methods in terms of their utility in DS screening 
and the number of invasive procedures needed to detect one case of DS, according to 
previous studies. 
 In 2005, the price of the combined FTS was estimated at circa 150 Euros (Wald et 
al. 2003, Autti-Rämö et al. 2005). Second trimester screening was judged to cost circa 
210 Euros. When structural ultrasound examination was included, the price of the 
combined FTS was approximately 190 Euros, and the price of second trimester 
screening was 220 Euros. Using both methods, five percent of screened women will 
receive a positive risk result, and the price of invasive procedures is the same – circa 
650–900 Euros for AFS or CVS (South Savonia Central Hospital District 2011, South 
Ostrobothnia Central Hospital District 2012). Thus the costs of serum marker 
screening are independent of the trimester in which the screen is performed, but 
unsurprisingly, FTS makes it possible to receive the results at a much earlier stage in 
the pregnancy. Integrated screening was estimated to cost approximately 265 Euros. 
 To standardise the methods of screening, the Finnish Ministry of Social Welfare 
and Health updated the Finnish Government Decree on Screenings in 2006. 
According to the Decree, all pregnant women should be offered a general early 
pregnancy ultrasound scan during week 10–14, the combined FTS with blood 
sampling in weeks 8–11 and the NT scan in weeks 10–12, or alternatively, the second 
trimester triple screening test using AFP, f -hCG, and uE3 in weeks 14–15 of the 
pregnancy. Ultrasound scans should be performed to test for severe structural 
abnormalities in week 18–21 or after week 24. 
 To increase the availability of foetal screening in all municipalities, the Finnish 
Ministry of Social Welfare and Health established a group of specialists in February–
December 2008. This group sent out a questionnaire to health care centres in October 
2008, which revealed that only 87 percent of municipalities offered the early 
pregnancy ultrasound scan, even though it should have been in use in each centre by 
January 2007. The combined FTS was offered by 79 percent. In addition, structural 
ultrasound during weeks 18–21 was offered by 83 percent, and after week 24, only by 
35 percent (The Ministry of Social Welfare and Health, 2009). 
 The Finnish Government Decree on Screenings during pregnancy was revised in 
2009. Under the new Decree, every municipality had to offer voluntary screening to 
pregnant women by the year 2010. All pregnant women must be offered the first 
trimester general ultrasound scan in weeks 10+0 – 13+6; chromosomal disorders must 
be primarily screened using the combined FTS with blood sampling at weeks 9+0 – 
11+6 and the NT measurement at weeks 11+0 – 13+6, or using the second trimester 
screening with blood sampling at weeks 15+0 – 16+6; and structural ultrasound 
examination must be offered at weeks 18+0 –  21+6 or after week 24+0.  
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2.4 THE FIRST TRIMESTER COMBINED SCREENING METHOD 
In a DS pregnancy, the foetus and especially the placenta mature and develop more 
slowly than they would in a healthy pregnancy. Screening aims to detect this 
protracted placental development, whose primary markers are unusually high levels 
of f -hCG and NT, and low levels of PAPP-A. 
 The FTS method combines the maternal serum markers – f -hCG and PAPP-A – 
with NT measurement of the foetus. The maternal serum samples are collected at 
maternity care units during gestational weeks 9+0 – 11+6. The samples are frozen and 
delivered to the analysing laboratory, where the concentrations of f -hCG and PAPP-
A are measured using a time-resolved fluoroimmunoassay. NT and CRL are 
measured at health care centers and maternity clinics by ultrasound-trained 
midwives and gynaecologists between weeks 11+0 and 13+6. 
 Screening in Finland is centralized in major accredited laboratories using the same 
method. Commonly 40–50 municipalities pay for FTS to be performed at a laboratory 
center or the laboratory of the central university hospital district. A pregnancy-
specific DS risk ratio is calculated in the analysing laboratory, based on the 
concentrations of f -hCG, and PAPP-A, and the NT measurement in millimetres. The 
calculated pregnancy-specific risk ratio either increases or decreases the maternal age 
risk ratio for DS pregnancy. A cut-off value of 1:250 is used – the risk is considered 
normal when the probability of having a foetus with DS is estimated at less than 1 in 
250, whereas the risk is considered higher than normal if the probability is estimated 
greater than 1 in 250. 
2.4.1 Risk calculation in the first trimester screening 
Risk calculation is performed in the laboratory, where all of the information 
concerning the mother is gathered and entered to the risk calculation software 
LifeCycle (PerkinElmer LifeSciences, Wallac, Turku, Finland). The name and social 
security number of the pregnant woman, the date on which the blood sample was 
collected, the mother’s weight, their history of smoking and previous DS 
pregnancies, the date of the beginning of their last menstrual period, and any 
medication they are taking, are received from the maternity care unit or the 
maternity clinic. The concentrations of f -hCG and PAPP-A are obtained using the 
Auto-DELFIA fluoroimmunoassay system. The NT and CRL measurements, the 
number of foetuses, and the date of the ultrasound scan are received from the 
maternity clinic. 
 In the risk calculation software, the patient's results of f -hCG, PAPP-A, and NT 
are compared to a population model described by a set of multivariate Gaussian 
distributions. The risk calculation programme provides a multiple of a median 
(MOM) value for each marker, proportional to gestational age. A MOM value is a 
measure of how far an individual test result deviates from the median of the 
population. The three markers, f -hCG, PAPP-A, and NT, are mathematically 
transformed into MOM values, by comparing the given value in this specific 
pregnancy with the median value for a normal pregnant population. For each 
median, a minimum of 50 values at each gestational week has been stored for 
comparison in the software. The MOM value is the measured value for the patient 
divided by the median for the statistic population. In risk calculation, medians are 
used rather than means because using means would distort the statistics, causing the 
distribution of values to lean to the left; in other words, the data would include more 
the small than the large values. 
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 In the overall population, the individual corrected MOM values for normal 
pregnancies should be 1.0. The median MOMs in DS pregnancies have been reported 
as 1.16–2.48 for f -hCG, 0.34–0.63 for PAPP-A, and 1.43–2.34 for NT (Cuckle and van 
Lith 1999, de Graaf et al. 1999, Crossley et al. 2002, Wald et al. 2003, Malone et al. 
2005, Koster et al. 2011), depending on the gestational age. These medians may need 
correction, as they vary by ethnic population, maternal and gestational age, maternal 
weight (Wapner et al. 2003, Malone et al. 2005, Kagan et al. 2009), the smoking habits 
of the pregnant woman (Lambert-Messerlian et al. 2009), whether the pregnant 
woman suffers from insulin-treated diabetes (Wald et al. 1994, Spencer et al. 2005), 
and the origin of the pregnancy – artificial or spontaneous (Gjerris et al. 2009, Kagan 
et al. 2009). Based on modern knowledge, no adjustments for maternal age or origin 
of the pregnancy are required. Version 2.1 of the LifeCycle risk calculation software 
package was used in the Eastern Finland Laboratory Centre and Kuopio University 
Hospital prior to May 2008. In this version, which was also used to analyse the data 
examined in this work, the concentrations of both f -hCG and PAPP-A were 
corrected for maternal weight, gestational age, and diabetes, but only the f -hCG 
concentration was corrected for smoking. 
 The risk calculation programme provides the likelihood ratio for DS based on 
maternal age, as well as the pregnancy-specific risk ratio based on the median MOMs 
of the combined screening markers and maternal age. The likelihood ratio provides 
an estimated probability that the foetus will have DS relative to the estimated 
probability of having a foetus with a normal karyotype. The possible risk ratio range 
with LifeCycle 2.1 is 1:5–1:50 000. A cut-off value of 1:250 is used to distinguish 
between screening positives (for which the estimated risk ratio is >1:250) and 
screening negatives (estimated risk ratio <1:250). This cut-off gives a fixed FPR of 
approximately five percent, i.e. there is a five percent chance that a screened woman 
will have a positive risk estimate. The likelihood ratio of 1:250 is comparable to the 
risk that an average 35 year old woman will have a baby with DS. The actual 
screening positive rate (or equivalently, the FPR) for the Eastern Finland Laboratory 
Centre between 2002 and 2008 was 3.7 percent since the median age of the screened 
population was 29.3 years. 
 If the pregnancy-specific risk ratio is considered normal (i.e. <1:250), the analysing 
laboratory will report the likelihood ratio to the maternity clinic or maternity care 
unit by mail, and the pregnant woman will be informed at her next visit. However, if 
the likelihood ratio is higher than 1:250, the result will be sent both by fax and by 
mail to the maternity clinic, which will direct the pregnant woman to medical 
genetics counselling and possible invasive testing with AFS or CVS. 
 In each series of sample measurements, a calibration curve is ran for internal 
quality control. The calibration reports are frequently examined by the hospital 
chemist in charge. For external quality control, supervised by an international quality 
assurance company (UK NEQAS, Edinburgh, Great Britain), the concentrations from 
quality control samples are measured and their MOM values as well as the specific 
DS risk ratio are calculated and sent to the quality control company, produce a report 
on the quality of the results. 
2.4.2 Free beta subunit of human chorionic gonadotrophin 
In addition to being a marker for pregnancy, hCG is used as a marker for chorionic 
(Smith et al. 2005) and testicular cancers (Klein 1993). HCG is a glycoprotein 
consisting of two subunits  (f -hCG) and  (f -hCG), which can either be non-
covalently bound to each other or exist as free subunits in the serum. HCG secreted 
by the placental trophoblasts appears in the circulation approximately one week after 
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conception and reaches its peak levels at approximately 8–12 gestational weeks. High 
levels of f -hCG are particularly common in DS pregnancies (Spencer et al. 1992). 
This protein is therefore most useful as a marker for DS screening in weeks 9-12 
(Cuckle and van Lith 1999, Wright et al. 2010). 
2.4.3 Pregnancy associated plasma protein A 
PAPP-A is a placental glycoprotein produced by the trophoblasts. Small amounts of 
PAPP-A are also present in non-pregnancy associated tissues such as the liver, heart, 
and kidney. High PAPP-A concentrations have been linked with asthma (Coskun et 
al. 2007), coronary artery disease, and an increased risk of myocardial infarction 
(Iversen et al. 2011), but the protein’s biological functions remain largely unknown. 
PAPP-A is known to be an insulin-like growth factor binding protein (IGFBP) 
protease and to increase the bioavailability of insulin-like growth factor (IGF). IGF, in 
turn, is believed to play a role in foetal growth (Lawrence et al. 1999, Bale and 
Conover 2005) by mediating trophoblast invasion into the decidua, and by regulating 
steroidogenesis and glucose and amino acid transport in the chorionic villi (Sun et al. 
2002). PAPP-A participates in growth regulation, and is therefore probably related to 
foetal development. In DS screening, PAPP-A is representable only during the early 
stages of pregnancy in weeks 0–13, because its serum concentration increases 
physiologically in later weeks as the pregnancy proceeds. PAPP-A is most useful for 
DS screening in week 9 (Cuckle and van Lith 1999, Tørring 2009). 
2.4.4 Pre-analytical phase 
The maternal venous blood samples are collected in health care centre laboratories. 
Blood (approximately three mL per sample) is collected by venipuncture into serum 
tubes, allowed to clot at room temperature for 30–90 minutes, and centrifuged at 
2000–3000 G, allowing 10 minutes for separation. The sera are stored in a refrigerator 
at four degrees of Celsius and are delivered to the analytical laboratory cold or 
frozen; they are stored at –20 degrees of Celsius. If a room temperature sample is 
received by the laboratory, it is processed normally, but the delivery temperature of 
the sample is noted when writing the report, and the validity of the result is 
estimated by a physician. 
2.4.5 Analytical phase 
In the Eastern Finland Laboratory Centre, the concentrations of f -hCG and PAPP-A 
are measured using a Wallac AutoDELFIA immunoanalyser (PerkinElmer, Turku, 
Finland) and ready-made reagents. The reagents are kept at a temperature of + 2 – - 4 
degrees of Celsius. Before the analysis, the standards are prepared and wash 
solutions for the plate and sample processors are poured. The samples are left to 
stand and thaw at room temperature for one and half hours prior to analysis. A full 
standard curve is run for each assayed plate. The information on samples and 
controls is entered on the work list in the AutoDELFIA workstation software. The 
samples, controls, and standard vials are then loaded and a schedule for the series is 
drawn up.  The bar codes on the test tubes are read by the analyser, which measures 
the concentrations of each marker, and prints out the results (PerkinElmer 2008). 
 During the analysis, f -hCG is attached to a samarium-labelled monoclonal 
antibody, i.e. an anti-f -hCG antibody produced by a single stem cell clone, whereas 
PAPP-A is attached to a europium-labelled monoclonal anti-PAPP-A antibody. The 
greater the concentration of f -hCG and PAPP-A in the sample, the greater the 
quantity of the fluorescent label that is bound. The concentrations of each marker are 
directly proportion to the intensity of the fluorescence emitted by the labelled 
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antibodies. The fluorescent label begins fluorescing after being displaced from the 
labelled antibody by the measuring solution and the label forms a chelate 
(PerkinElmer 2008). 
 F -hCG concentrations are reported in ug/L; the measured and reported 
concentrations range from 2–200 ug/L. PAPP-A concentrations are reported in mU/I 
(arbitrary units); PAPP-A measurements range from 10–2000 mU/I, and the results 
range from 50–10 000 mU/I. The lowest limits of detection for f -hCG and PAPP-A 
are 0.2 ng/mL and 5 mUI/L, respectively (PerkinElmer 2008). If the measured 
concentration in the sample exceeds the highest value standard, the sample must be 
diluted using the DELFIA Diluent II solution; typically, a 1:10 dilution is prepared in 
the first instance. The sample is then re-analyzed and the result is multiplied by the 
dilution coefficient to determine the true concentration. 
 AutoDELFIA and DelfiaXpress systems, which yields similar results to those 
obtained with AutoDELFIA, are used in Finnish laboratories, but other assay systems 
are also available, including Kryptor (Brahms AG, Henningsdorf, Germany) and 
Immulite (Siemens Healthcare Diagnostics., Deerfield, IL, USA) immunoassay 
systems, which give measured PAPP-A concentrations that are typically twice as 
high as those measured with AutoDELFIA. This, naturally, is accounted for in the 
risk calculation algorithm. 
2.4.6 Post-analytical phase 
The AutoDELFIA time-resolved fluoroimmunoassay kit exhibits both within- and 
between-assay variation. Both are below 3.4 percent for f -hCG at concentrations of 
4–157 ug/L, while the corresponding values for PAPP-A are <2.4 and <4.0 percent, 
respectively, in the detection range of 44–7300 mUI/L. Internal quality control is 
performed by calibration before each assay. External quality control is supervised by 
an international quality assurance company (UK NEQAS, Edinburgh, Great Britain). 
The quantification of f -hCG and PAPP-A is very accurate and reproducible. The 
most important sources of error in the biochemical screening relate to sample 
collection and storage (Palomäki et al. 2009, Lambert-Messerlian et al. 2006). 
2.4.7 Ultrasonic nuchal translucency measurement 
Foetal NT, otherwise known as foetal neck oedema – the unusually thick layer of 
fluid imaging with a low grade echo – is associated with chromosomal abnormalities, 
cardiovascular defects (Hyett et al. 1996), skeletal dysplasias (Hyett et al. 1997, Khalil 
et al. 2011), infectious diseases during pregnancy (Sebire et al. 1997), and some rare 
genetic syndromes. The accumulation of foetal subcutaneous fluid is referred to as 
nuchal translucency in the first trimester, whereas in the second trimester it is called 
a nuchal fold. It should ideally be measured in weeks 11+0 – 13+6 because NT is 
typically seen during weeks 10–14 but disappears afterwards. NT is routinely 
measured by ultrasound during pregnancy weeks 11–13, with the measurement 
being made transabdominally or transvaginally; the results obtained using both 
methods are congruent and the measurement is successful in 95 percent of women 
(Whitlow et al. 1999, Nicolaides, 2004). 
 NT is measured in the back of the foetal cervical spine, from the external border of 
soft tissue to the internal border of the skin (Figure 1). The greatest possible 
magnification should be used during the measurement, and the image is magnified 
so that the foetus fills approximately two thirds of the monitor. Scanning is 
maintained during spontaneous foetal movement in order to attain the best possible 
sagittal scan position and thus the ‘view’ that best distinguishes between the skin 
and the foetal membranes. The umbilical cord may be wrapped around the neck, 
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causing its apparent size to increase by up to 0.8 millimetres; when wrapped around 
in this way, the umbilical cord can be misinterpreted as NT. NT is dependent on the 
gestational age, which is determined by measuring foetal CRL. Using CRL, 
gestational age can be determined with an accuracy of ± three days (Taipale and 
Hiilesmaa 2001). CRL measurement is recommended for foetuses whose length is 
less than 60 millimetres. If the foetus is taller than this, the biparietal diameter or 
femur length should be used.  
 
 
 
Figure 1. NT measurement of a foetus during the first trimester. The nasal bone can also 
be seen (Department of Gynaecology and Obstetrics, Kuopio University Hospital). 
 
 NT is the most efficient ultrasonic measure for aneuploidies. The MOM of NT is 
not dependent on maternal weight (Gilbert et al. 2001) or maternal age (Taipale et al. 
1997), unlike the MOMs of the biochemical markers. However, a foetus with DS 
might seem completely normal in a structural ultrasonic examination, and only 50–70 
percent of affected foetuses exhibit extensive NT (Taipale et al. 1997, Pajkrt et al. 
1998). NT increases with the duration of the pregnancy; the mean NT in normal 
pregnancies at week 9 is approximately 0.7 mm, rising to 1.2 mm in week 10 and 
1.5 mm in week 13. According to our records, in DS pregnancies the mean NT at 
week 10 is 1.8 mm, rising to 2.4 mm in week 11, 2.9 mm in week 12, and 3.2 mm in 
week 13. Consequently, the average MOM value for DS pregnancies is 
approximately 2: 1.9–2.0 at week 10, 1.8–2.1 at week 11, 1.6–2.5 at week 12, and 1.4–
2.0 at week 13 (Crossley et al. 2002, Wald et al. 2003, Malone et al. 2005, Koster et al. 
2011). 
 High NT values are sometimes observed in chromosomally normal foetuses. In 
cases where a large NT is observed by but the chromosomes are shown to be normal 
by AFS or CVS, the foetus has an increased risk of congenital heart defects and many 
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other anomalies (Souka et al. 1998, Nicolaides et al. 2002, Mendoza-Caamal et al. 
2010). The most probable aetiology of NT in both euploid and aneuploid foetuses is 
heart failure due to abnormal or delayed embryonic and foetal development of the 
heart and other organs. The observation of a large NT therefore requires that a 
structural and cardiac ultrasonic scan be performed by a specialist. 
 The ultrasonic measurement of NT has been shown to be the most challenging 
component of the combined FTS. In Finland, ultrasound-trained midwives usually 
perform the measurements, whereas in many other countries the first trimester 
ultrasound scans are often carried out by gynaecologists or radiologists. The time 
reserved for each pregnant woman per scan in Finland is usually 20 minutes, 
whereas 30 minutes is common abroad. However, it has been estimated that it takes 
three years and approximately 700 measurements for a trained midwife to achieve 
adequate precision and repeatability (Taipale et al. 2003). To ensure the quality of the 
measurements, it is recommended that each practitioner conduct at least 200 each 
year (Tekay 2009). 
2.5 SPECIAL SITUATIONS IN FIRST TRIMESTER SCREENING 
2.5.1 Multiple pregnancies 
Screening of twin pregnancies is problematic. In normal twin pregnancies, the 
concentrations of the serum markers are approximately twice as high as in normal 
singleton pregnancies. Unusually high or low marker concentrations in a screened 
twin pregnancy indicate a risk of adverse events, but it is impossible to say which of 
the foetuses may have a chromosomal abnormality, especially if their NTs are 
normal (Spencer and Nicolaides 2003, Audibert and Gagnon 2011). 
 The ultrasonic measurement establishes whether the pregnancy is singleton or 
multiple. In twin pregnancies, observations are conducted to determine whether the 
pregnancy is mono- or dichorial, in other words whether the foetuses have a 
common foetal chorionic membrane or whether each has one of their own. 
Determination of chorionity is extremely meaningful because monochorial 
pregnancies are inescapably monozygotic, i.e. the foetuses are identical twins and 
originate from the same oozygote, whereas in dichorial pregnancies, 90 percent of 
the foetuses are dizygotic and originate from two different eggs. In dizygotic 
pregnancies, the risk of trisomy is doubled due to twinning, whereas in monozygotic 
pregnancies the age risk is the same as in singleton pregnancies, but either with both 
foetuses having a normal or an abnormal karyotype. NT measurement remains 
useful as a screening method in twin pregnancies whereas serum markers are merely 
directional (Spencer 2000, Spencer and Nicolaides 2003). On the other hand, if 
chorionity is assured by ultrasound, biochemical markers improve the DR as 
compared to NT measurement alone, and can be used advisedly in multiple 
pregnancies (Audibert et al. 2011, Prats et al. 2012). 
2.5.2 Assisted reproductive technology 
It has been reported that the levels of all three markers used in the combined FTS are 
changed in assisted reproductive technology (ART) pregnancies, but there is no 
evidence that the frequency of DS is higher in pregnancies induced using assisted 
reproduction than in those with spontaneous origin  (Liao et al. 2001, Hui et al. 2006, 
Gjerris et al. 2009). The median f -hCG MOM level in chromosomally normal IVF 
pregnancies has been shown to range from 0.84–1.21 depending on the gestational 
age, while the median PAPP-A MOM in these pregnancies has been reported to 
range from 0.75–1.0 (Orlandi et al. 2002, Ghisoni et al. 2003, Tul and Novak-Antolic 
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2006, Anckaert et al. 2008, Amor et al. 2009, Gjerris et al. 2009, Kagan et al. 2009). The 
median NT MOM values have ranged between 1.0–1.6 MOM (Liao et al. 2001, 
Orlandi et al. 2002, Hui et al. 2006, Gjerris et al. 2009). Hence, the estimates of these 
markers tend to increase the FPR in ART pregnancies (Heinonen et al. 1996b, Orlandi 
et al. 2002, Tul and Novak-Antolic 2006, Amor et al. 2009, Gjerris et al. 2009, Kagan et 
al. 2009). 
2.5.3 Other aneuploidies than Down's syndrome 
Besides DS, the combined FTS can be used for screening of other major trisomies 
such as trisomies 13 and 18 (Spencer and Nicolaides 2002, Wapner et al. 2003, 
Breathnach et al. 2007, Kagan et al. 2008). During the first trimester, the MOM of f -
hCG in trisomies 13 and 18 has been reported as 0.16–0.41, the MOM of PAPP-A as 
0.0.9–0.36, and the MOM of NT 1.17–2.82 (Spencer and Nicolaides 2002, Breathnach 
et al. 2007, Kagan et al. 2008). Since version 2.1, the LifeCycle risk calculation 
software has had a standard algorithm for calculating the risk ratio for trisomy 18. 
2.5.4 Anomalies 
Foetal structures are inspected in early sonographic examinations and during the NT 
measurement. Anomalies such as an absent umbilical cord, a large ventral wall 
defect with herniation (Murphy and Platt 2011), or the absence of a limb can be 
detected during these inspections (Rice et al. 2011). There is no clear evidence 
indicating that such anomalies are associated with any alteration of first trimester 
biochemistry (Aitken et al. 1993), although there is a reported link between an 
increased risk ratio in the combined FTS and the risk of anomalies, such as abnormal 
ductus venous flow and tricuspid regurgitation (Ozkaya et al. 2009). 
2.5.5 Miscarriages 
If during the first trimester approximately five percent of pregnancies are miscarried, 
three percent of women who undergo the combined FTS would have blood samples 
taken but would then have their pregnancies spontaneously aborted before the NT 
scan, and two percent of those who have all three markers of the combined FTS 
measured, would undergo spontaneous abortion after the combined FTS. 
Furthermore, some pregnancies are spontaneously aborted after CVS or AFS – some 
of these are due to the invasive testing and some would have been aborted anyway. 
In cases of miscarriage, the laboratory will not receive the diagnosis of the aborted 
foetus, and so the true DR from screening is unknown.  
2.5.6 Adverse pregnancy outcomes 
It has been observed that the concentrations of f -hCG and especially PAPP-A are 
lower than normal for adverse pregnancy outcomes with a normal foetal karyotype, 
such as PD, PE, and SGA (Smith et al. 2002, Tul et al. 2003, Dugoff et al. 2004, Liu et 
al. 2004, Brameld et al. 2008, Spencer et al. 2008a, Spencer et al. 2008b, Poon et al. 
2009). Low levels of f -hCG and PAPP-A probably reflect impaired placentation. 
There has been some discussion on whether such pregnancies should be monitored 
closely. To date, no risk calculation algorithms for adverse pregnancy outcomes have 
been established. 
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3 Diagnosis of chromosome disorders 
3.1 INDICATIONS FOR CHROMOSOME DETERMINATION 
When screening indicates that a pregnant woman is subject to an increased risk of 
DS, she and her family are given an appointment for medical genetics counselling. If 
the expectant family is willing, the foetal chromosomes are tested by AFS or CVS. 
The sampling takes place at the maternity clinic. Chromosome determination is 
performed in the department of clinical genetics, which is also in charge of genetic 
counselling if the foetal chromosome is found to be abnormal. 
 Aside from a high risk ratio in foetal screening, other indications for chromosome 
analysis are high maternal age – age limits are municipality-specific and range from 
35 to 40 (Viisainen 1999), a known chromosomal abnormality in either parent or one 
of their older children, and the detection of a structural development disorder by 
ultrasound. Such structural abnormalities include ventral hernia, talipes equinovarus 
(i.e. clubfoot deformity), heart defects, and other foetal abnormities such as an NT 
above three millimetres, plexus chorioideus cyst, dilated renal pelvises, emphasized 
intestinal echo or increasing IUGR. 
3.2 METHODS FOR CHROMOSOME DETERMINATION 
The choice of whether to use AFS or CVS depends on gestational age. Invasive 
procedures to determine the foetal chromosome necessitate a transabdominal 
puncture with a thin needle to the uterus. In AFS, there is a 0.5 percent risk of 
miscarriage, and in CVS, the risk is estimated to be 0.5-1.0 percent (Tabor and 
Alfiveric 2010). The aspired sample is injected onto a Petri dish and taken to the 
laboratory of clinical genetics. The sample is then processed and labelled for 
immunofluorescence. The chromosomes are identified and counted under a 
fluorescence microscope, and a chromosomal map is made for examination (Figures 
2a and 2b). Certain chromosomes can be detected by fluorescent in situ hybridization 
using gene probes. Chromosome determination by fluorescent in situ hybridization is 
very reliable: over 99 percent of examinations lead to an accurate result. 
Chromosomal mosaicism can cause uncertainty because it means that the sample 
will contain both chromosomally normal and chromosomally abnormal cells. If the 
CVS data indicates mosaicism, an AFS sample is taken. AFS is more reliable and 
generates mosaic results less frequently than CVS. If AFS sampling indicates 
mosaicism, an appointment with a specialist in medical genetics is arranged to 
discuss the finding. 
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Figure 2a. 
A normal euploid 
chromosome of a male 
foetus (46,XY) 
(Laboratory of Clinical 
Genetics, Eastern 
Finland Laboratory 
Centre, Kuopio, 
Finland). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2b. 
A chromosome of a 
male foetus with 
Down's syndrome 
(47,XY,+21) 
(Laboratory of Clinical 
Genetics, Eastern 
Finland Laboratory 
Centre, Kuopio, 
Finland). Both 
chromosomes in 
Figures 2a and 2b are 
taken from an 
amniotic fluid sample 
during early second 
trimester. 
 
 
 
 CVS can be performed after the 10th gestational week. The placenta is punctured 
using ultrasonic guidance, and placental tissue is aspired. The sample is incubated in 
a thermic cabinet at 37 degrees of Celsius, and frequently examined under a 
microscope to observe cell division. Mitosis is usually observed in less than a week, 
and the chromosomes are stained so that they can be identified and counted under a 
microscope. If no dividing cells are clearly observed, the sample is cultivated and the 
result is given in 3–4 weeks. In practice, CVS is usually taken after the 11th week, and 
a result is obtained in 5–7 days. 
 AFS is usually performed in week 15 or 16 of gestation. The sample is aspired 
from the uterine cavity, where the needle can be seen by ultrasound. The amniotic 
fluid always includes some foetal cells, and the cells are cultivated for chromosome 
determination. Completion of the result typically takes two or three weeks. The 
concentration of AFP is routinely measured from the amniotic fluid to monitor foetal 
structural abnormalities that might not have been seen in ultrasonic measurements, 
such as spina bifida or congenital nefrosis. 
 Cordocentesis i.e. foetal blood sampling from the umbilical chord is not a 
recommended option for determination of the foetal chromosome, since the risk of 
miscarriage is as high as 15 percent (Bernaschek et al. 1995). However, if there are 
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justifiable reasons for sampling in this way, the sample can be collected at any point 
before week 18 of gestation. 
3.3 FURTHER ACTIONS AFTER DIAGNOSIS 
If AFS or CVS indicate that the foetus has chromosomal abnormalities, the parents 
should be offered medical genetics counselling or a meeting with a perinatologist. 
Counselling is given to ensure they understand the meaning of the particular 
abnormal karyotype, and to allow them to plan their actions. If the parents decide to 
continue the pregnancy, follow-up monitoring during the pregnancy, delivery, and 
possible care of the newborn should be organized as best possible. If the parents 
decide to terminate the pregnancy, they can apply for termination from the National 
Institute of Health and Welfare. Permission for termination can be granted on the 
grounds of foetal developmental disorder or disability at any point up to the 24th 
week of gestation. If the pregnancy is terminated due to a foetal developmental 
disorder, the nature of the disorder is verified by examining and photographing the 
aborted foetus, examining its chromosomes, and performing an autopsy. Genetic 
counselling can thus provide the parents with information on the likelihood that the 
abnormality will affect any future pregnancies they may have and ensure they 
receive proper care during any later pregnancy. 
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4 Aims of the study 
The studies reported in this thesis were conducted to investigate the factors 
influencing the concentrations of the biochemical markers in the combined FTS. 
 A key objective was to examine the effects of the TTP on the first trimester DS 
markers in spontaneous, chromosomally normal pregnancies, and to compare the 
results to those in IVF pregnancies. Our main interest was in the concentrations of f -
hCG and PAPP-A in pregnancies with a prolonged TTP. 
 Previous studies have reported altered concentrations of f -hCG and PAPP-A in 
pregnancies with PD, PE, and SGA. We investigated the profile of the biochemical 
markers in adverse pregnancy outcomes, including PA, in chromosomally normal 
pregnancies. 
 The concentrations of f -hCG and PAPP-A vary with maternal age, and the DR of 
the combined FTS has been known to be higher in women aged >35 years than in 
women aged 35 years. The numbers of invasive procedures needed to detect one DS 
pregnancy in women between 15 and 48 years of age were examined according to 5-
year age groupings. 
 Finally, the performance of the first trimester biochemical screening markers at 
different maternal ages was analysed. 
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5 Material and methods 
5.1 STUDY DATA 
The investigations were conducted using case-control studies. Screening data were 
collected in the Eastern Finland Laboratory Centre, Helsinki Central University 
Hospital Laboratory Centre, Oulu University Hospital Laboratory, and Seinäjoki 
Central Hospital Laboratory. The maternal and pregnancy data were collected from 
the Departments of Gynaecology and Obstetrics of Helsinki, Kuopio, and Oulu 
University Hospitals, as well as Seinäjoki Central Hospital. The results of 
chromosome examinations were collected from each laboratory centre's or hospital's 
Department of Clinical Genetics. The data used in the study are presented in Table 2. 
 
Table 2. Data used in the study 
 
Work Data source N Follow-
up 
Study 
design 
Pregnanc
y 
karyotype 
Study problem 
I Kuopio University 
Hospital 
  1 385 Jan 
2005 – 
Dec 
2007 
Obser-
vational 
case-
control 
Normal Time to 
pregnancy vs. 
f -hCG and 
PAPP-A 
concentrations 
II Kuopio University 
Hospital 
  2 844 Jan 
2005 – 
Dec 
2007 
Retro-
spective 
case-
control 
Normal Adverse 
pregnancy 
outcome vs.  
f -hCG and 
PAPP-A 
concentrations 
III Helsinki, Oulu, 
and Kuopio 
University 
Hospitals;  
Central Finland, 
Kymenlaakso, 
Mikkeli,  
North Carelia, and 
Seinäjoki Central 
Hospitals 
65 600 May 
2002 – 
Dec 
2008 
Retro-
spective 
case-
control  
DS 
or  
normal 
Maternal age 
vs. the 
performance of 
the combined 
screening  
IV Helsinki, Oulu, 
and Kuopio 
University 
Hospitals;  
Central Finland, 
Kymenlaakso, 
Mikkeli,  
North Carelia, and 
Seinäjoki  
Central Hospitals 
76 949 May 
2002 – 
Dec 
2008 
Retro-
spective 
case-
control 
DS 
or  
normal 
Maternal age 
vs. the 
performance of 
the biochemical 
screening 
 
 In studies I–II, the investigated factors hypothesized to influence on the combined 
FTS were: maternal age, origin of the pregnancy (spontaneous/IVF), the TTP in 
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spontaneous pregnancies, and the outcome of the pregnancy 
(normal/PA/PD/PE/SGA). In work I, spontaneous pregnancies were classified into 
three groups by TTP: 0–12 months (the reference group, N=1164), 13–24 months 
(N=112) and ≥25 months (N=70). Screening data from IVF pregnancies were collected 
for comparison (N=39). The size of the total study population was 1385. In work II, 
the four study groups were pregnancies with PA (N=17), PD (N=213), PE (N=175), 
and SGA (N=275) plus a reference group with a normal outcome (N=2164). Reference 
pregnancies were taken to have a normal outcome if the foetus had an euploid 
chromosome, the pregnancy duration was at least 38 weeks, and the mother and 
newborn did not require any prenatal, perinatal or postnatal follow-up, care or 
intervention over and above that administered by routine. The size of the total study 
population in this work was 2844. The sample size in study I was smaller than that in 
study II since the number of IVF pregnancies with no missing data was only 39, and 
TTP is not typically requested in patient-reported information. 
 In studies III–IV, pregnancies with euploid karyotypes were used as references, 
and singleton pregnancies with DS were considered cases. In the combined FTS, the 
number of DS pregnancies was 188; and in biochemical screening the number of DS 
pregnancies was 221, so there were 33 cases without NT data. The size of the entire 
screened population was 76 949, of which 65 600 had been screened using all three 
markers, including NT. The results were compared in 5-year age groups (≤19 years, 
20–24 years, 25–29 years, 30–34 years, 35–39 years, 40–44 years, and ≥45 years). 
5.2 PATIENT DATA 
The data for studies I–II was collected from the same pregnant population in the 
Kuopio catchment area. Screening and follow-up data on the index pregnancy were 
collected between January 1 2005 and December 31 2007 from the databases of the 
Eastern Finland Laboratory Centre, and the Department of Gynaecology and 
Obstetrics in Kuopio University Hospital. The results from the multicentre study 
were published in papers III–IV. The information was collected in Helsinki, Kuopio, 
Oulu, and Seinäjoki between May 1 2002 and December 31 2008. 
 The patient-reported information included the weight and height of the mother, 
information on whether she had any chronic diseases (hypertension or diabetes), her 
smoking habits (yes/no), the waiting time to pregnancy measured from the start of 
attempts to become pregnant to the observation of an actual pregnancy, possible 
prior pregnancy complications, and whether she had undergone infertility treatment. 
Systematically gathered information included the FTS results (the age of the mother, 
maternal serum f -hCG and PAPP-A concentrations and the NT of the foetus), the 
method of conception (spontaneous or IVF), –, body mass index (BMI) before and at 
the end of the index pregnancy, pregnancy duration, possible pregnancy 
complications, pregnancy outcome (normal/abnormal chromosomes, and the 
karyotype; PA/PD/PE/SGA), the method of chromosome determination (AFS/CVS), 
gender of the foetus, and birth weight. PE was indicated in cases where blood 
pressure measurements above >140/90 mmHg were recorded on multiple occasions, 
with proteinuria >0.3 g/day. PD was indicated by births occurring before the end of 
the 37th week of gestation. SGA was indicated by the sex- and age-adjusted birth 
weight falling within the 10th percentile according to our records, and PA was 
diagnosed clinically. 
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5.3 THE SCREENING METHOD 
Screening was conducted using the combined FTS method. Serum samples were 
collected between weeks 8+0 and 12+6, and NT measurements were conducted 
between weeks 10+0 and 13+6. The maternal biochemical data were analyzed 
retrospectively. For studies I-III, this meant using the original DS risk ratios from the 
combined FTS. However, in study IV, data from the population examined in study 
III were analyzed, focusing exclusively on information on the serum markers f -hCG 
and PAPP-A; the DS risk ratios for the biochemical screening were re-calculated 
using the combined screening data with NT results excluded from the risk 
assessment. 
5.4 ETHICS 
The study was approved by the Ethical Research Committees of Helsinki, Kuopio, 
and Oulu University Hospitals, and the Institutional Review Boards. The study was 
planned to examine the quality of the combined FTS, and thus provide information 
for internal quality control. The Committees gave permission for the results to be 
published. In addition, permission to access the national registers of births and 
newborns, induced abortions, and anomalies, was sought from the Ministry of 
Welfare and Health and STAKES in Autumn 2006, and granted a year later for 2006–
2009. The combined FTS was performed according to the recommendations of the 
Finnish Ministry of Social Affairs and Health. The study was performed in 
accordance with the Helsinki Declaration. Patient data was handled with 
confidentiality, and according to the instructions of all participating hospitals and 
laboratories. 
5.5 STATISTICS 
Data concerning the pregnancies screened in the first trimester were registered, and 
the parameters of variables were tabulated. It was determined which pregnancies 
had been tested using AFS or CVS, and the results of the chromosome 
determinations were collected. On the basis of the screening results and chromosome 
determinations, the FPR for each group was collected, and the DR in each group was 
calculated. The DR for each age group (<20, 20–24, 25–29, 30–34, 35–39, 40–44, and 
≥45 years) was calculated as the ratio of true positive cases detected in screening 
divided by the total number of Down’s syndrome cases. 
 The differences between the subject and reference groups were tested for 
statistical significance. In studies I, II, and IV, the median MOMs for f -h and PAPP-
A concentration and for the NTs of different study groups were compared using 
two-tailed pooled t-tests, since the MOMs fitted Gaussian distributions. Continuous 
variables (mean maternal age, mean weight gain during pregnancy, mean birth 
weight, the mean duration of the pregnancy) were compared using Student's two-
way t-tests. Chi-square tests were used to analyze dichotomous variables (yes/no 
responses regarding FPR and DR, chronic diseases – hypertension and diabetes, 
gestational diseases – diabetes and hepatosis, smoking during pregnancy, prior 
infertility treatment, prior miscarriages, prior induced abortions, prior foetal death, 
maternal obesity, primigravida, placenta praevia, adverse outcome, caesarean 
section). The odds ratios for adverse outcomes at different serum marker MOM 
levels were calculated. Fisher's exact test was used when there were fewer than five 
units in any of the classes. In study III, the adjusted R-square with p-value of F-test 
was used to evaluate the goodness of fit in non-linear regression analysis. When P 
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values were less than 0.05, differences were considered statistically significant. Data 
in studies I, II, and IV were analyzed using the SAS software package (SAS Institute 
Inc., Cary, NC, USA). In study III, data analyses were conducted using the SPSS 
software package (SPSS Inc., Chicago, IL, USA). 
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6 Results  
6.1 THE TIME TO PREGNANCY IN EUPLOID PREGNANCIES AFFECTS 
THE COMBINED FIRST TRIMESTER SCREENING MARKERS AND 
RESULTS 
A prolonged TTP of ≥25 months was associated with a higher mean maternal age 
(p<0.01), obesity (p<0.01), chronic diseases (p=0.04), and prior miscarriages (p<0.01). 
However, despite the clustering of maternal risk factors in the group with prolonged 
TTP, no statistically significant differences were found in terms of pregnancy 
duration, mean birth weight, or PA, PD, and PE. These risks and adverse outcomes 
were associated with IVF pregnancies (p≤0.02), as was the incidence of LBW, even 
though the prevalence of maternal risk factors in the IVF group was closer to those 
with no delay in getting pregnant than those with TTP values of ≥13 months. 
 The median MOM for PAPP-A was lower in the groups with TTP values ≥25 
months and that had undergone IVF as compared to the reference group with short 
TTP (p<0.01 in both groups). No statistically significant differences were found in the 
median MOMs for fβ-hCG and NT between the groups. The study group with the 
longest TTP (≥25 months) had the highest FPR (p<0.01). The proportion of SGA in the 
study population was 9.4 percent. The median PAPP-A concentration for all the SGA 
pregnancies investigated was 0.85 MOM, whereas for pregnancies resulting in 
infants with normal birth weights, the PAPP-A MOM was 0.98 MOM (p<0.01). The 
combined FTS results according to TTP are presented in Table 3. 
 
Table 3. First trimester Down's syndrome screening results for the study groups 
compared to a reference group for which the time to pregnancy was 0–12 months 
(N=1385) 
 
Time to 
pregnancy 
 
No infertility treatment Assisted reproduction 
0–12 
months 
N=1164 
13–24 
months 
N=112 
 
 
P 
≥25 
months 
N=70 
 
 
P 
IVF 
 
N=39 
 
 
P 
Median  
f -hCG 
MOM 
 
 
0.97 
 
 
1.05 
 
 
0.14 
 
 
0.94 
 
 
0.73 
 
 
0.91 
 
 
0.80 
Median 
PAPP-A 
MOM 
 
 
1.03 
 
 
1.03 
 
 
0.91 
 
 
0.83 
 
 
<0.01 
 
 
0.84 
 
 
<0.01 
Median NT 
MOM 
 
0.98 
 
0.96 
 
0.61 
 
0.94 
 
0.39 
 
1.02 
 
0.19 
FPR (%) 2.1 2.7 0.66 12.9 <0.01 2.6 0.76 
 
6.2 LOW PAPP-A IS A MARKER FOR ADVERSE PREGNANCY 
OUTCOMES WITH PATHOLOGY OF THE PLACENTA 
Maternal hypertension was associated with all adverse outcomes studied: PA, PD, 
PE, and SGA (p<0.01 in each). Diabetes was most common in women with PE and 
PD (p<0.001 in both groups). Obesity and gestational diabetes were most common in 
women with PE (p<0.01 for both). The highest occurrence of placenta praevia was in 
the PD group (p<0.01). The proportion of primigravidas was significantly higher in 
the groups with PE and SGA (p<0.001 for both groups).  
28 
 
 
 The mean pregnancy duration was shorter in all study groups as compared to the 
reference group (p<0.01 in each group). Mean foetal birth weight was lowest in the 
PA group (p<0.01). The mean placental weight / birth weight ratio expressed as a 
percentage was higher in all study groups as compared to the reference group; the 
same was true for Caesarean sections, abnormal Apgar scores, the need for intensive 
care, and infants with LBW (p<0.01 in each group). 
 The median MOMs for f -hCG and PAPP-A were lower in the PD, PE, and SGA 
groups than in the reference group (p≤0.02 in each group). However, the median 
MOMs for f -hCG and PAPP-A in the PA and the reference groups appeared to be 
statistically similar. No statistically significant differences between the groups were 
found in terms of the median MOMs for NT. The highest FPR was observed in the 
PD group (p<0.01). The combined FTS results in pregnancies with adverse outcomes 
are presented in Table 4. 
 
Table 4. First trimester Down's syndrome screening in the PE, PED, SGA and PA study 
groups compared to the reference group (N=2844) 
 
Characteristic 
Normal 
outcome 
N=2164 
PE 
 
N=175 
 
 
P 
PD 
 
N=213 
 
 
P 
SGA 
infants 
N=275 
 
 
P 
PA 
 
N=17 
 
 
P 
Median f -
hCG MOM 
 
0.99 
 
0.86 
 
0.02 
 
0.92 
 
0.02 
 
0.90 
 
<0.01 
 
0.92 
 
0.62 
Median 
PAPP-A 
MOM 
 
 
0.99 
 
 
0.79 
 
 
<0.01 
 
 
0.80 
 
 
<0.01 
 
 
0.79 
 
 
<0.01 
 
 
1.00 
 
 
0.76 
Median NT 
MOM 
 
1.05 
 
1.06 
 
0.63 
 
1.06 
 
0.52 
 
1.05 
 
0.75 
 
1.22 
 
0.59 
FPR (%) 2.6 5.1 0.06 6.6 <0.01 4.7 0.05 0 1.00* 
*When a class included less than 5 variables, Fisher´s exact test was used 
 
 For all adverse pregnancy outcomes, the odds ratios of f -hCG MOM <1.0 were 
1.16–1.76, and the odds ratio of PAPP-A MOM <1.0 1.09–2.06. In pregnancies with PD 
and SGA, the odds ratio with decreasing PAPP-A MOM increased linearly, whereas 
in pregnancies with PE, the odds ratios were variably higher at low PAPP-A MOMs. 
In PA pregnancies, the odds ratios were most variable; 1.09 for PAPP-A MOM <1.0, 
0.76 for PAPP-A MOM <0.8, 0.52 for PAPP-A MOM <0.6, and 1.73 for PAPP-A MOM 
<0.4. 
6.3 MORE INVASIVE TESTS ARE NEEDED FOR YOUNG WOMEN TO 
DETECT A DOWN’S SYNDROME PREGNANCY 
The DR for the combined FTS was 81.9 percent. The mean maternal age in the study 
population was 29.3 years. Using a cut-off value of 1:250, the FPR was 4.3 percent. 
The number of invasive procedures needed to detect one case of DS in the entire 
population was 1:22. Using an FPR of five percent, the cut-off was calculated as 
1:283, and the overall DR would have improved to 82.4 percent with one additional 
detected DS pregnancy. However, the increase in FPR from 4.3 to 5.0 percent would 
mean an additional loss of five healthy fetuses due to the increased number of 
invasive procedures needed to detect one additional case of DS. 
 The lowest DR (63.6 percent) and the highest number of invasive tests needed 
were in the age group of 25–29 years (51 tests needed for each case of DS). The 
highest DR (92.7 percent) and the lowest number of invasive procedures needed 
were in the age group of 40–44 years (14 tests needed). Using a fixed five percent FPR 
for all age blocks did not improve the DRs: only one extra case of DS would have 
been detected, in the group of women aged between 25 and 29, and so the number of 
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invasive tests needed to detect one case of DS would have increased from 51 to 87. 
Moreover, six cases in women aged between 35 and 39 would have been missed, 
decreasing the DR from 83.3 to 75.0 percent, and 14 cases would have been missed in 
women aged between 40 and 44, decreasing the DR form 92.7 percent to 58.5 percent. 
Table 5 compares the performance of the combined FTS at a fixed FPR of five percent 
and a fixed cut-off limit of 1:250. 
 
Table 5. Comparison of the performance of the combined FTS between fixed FPR of 5 % 
and fixed cut-off limit of 1:250 in the screened population (N=65600), and the Down's 
syndrome pregnancies (N=118) 
 
    Cut-off 1:250 FPR 5 % 
Age 
(yrs) 
N 
(%) 
T21 
N 
T21 
(%) 
FPR 
(%) 
FP 
N 
TP 
N 
DR 
(%) 
NIP
N 
Cut-
off 
FP 
N 
TP 
N 
DR 
% 
NI
PN 
    –19 2.4 0 0 1.9 35    1:485 92    
20–24 17.8 14 7.4 2.3 315 11 78.6 29 1:469 685 11 78.6 62 
25–29 34.1 22 11.7 2.7 708 14 63.6 51 1:420 1312 15 68.2 87 
30–34 28.8 37 19.7 3.2 709 29 78.4 24 1:370 1108 30 81.1 37 
35–39 14.0 72 38.3 9.2 991 60 83.3 17 1:110 539 54 75.0 10 
40–44 2.8 41 21.8 24.0 517 38 92.7 14 1:20 107 24 58.5 4 
45– 0.1 2 1.1 48.1 37 2 100.0 19 1:25 4 2 100.0 2 
FP = false positives 
TP = true positives 
NIPN=number of invasive procedures needed to detect one T21 
 
6.4 MATERNAL AGE AFFECTS THE MEDIANS OF THE BIOCHEMICAL 
MARKERS 
The median MOM for f -hCG across the entire studied population was 0.98. The 
median MOM was 0.99 in women aged <35 years, whereas in women aged ≥35 years 
it was 0.94 (p<0.01). The median MOM of PAPP-A in the entire screened population 
was 0.94. In women aged <35 years, the median MOM was 0.92, and in women aged 
≥35 years it was 0.95. None of the differences between age groups were statistically 
significant. In DS pregnancies, the overall median MOM for f -hCG was 1.58, and 
the overall median MOM for PAPP-A was 0.40. No statistically significant 
differences were found in f -hCG or PAPP-A MOMs in DS pregnancies between 
women aged <35 years and ≥35 years. Across the entire screened population, there 
was an increasing trend in f -hCG MOM values and a decreasing trend in PAPP-A 
MOM values as gestational age increased. In DS pregnancies, the MOMs of f -hCG 
and PAPP-A varied as gestation progressed in women aged <35 years, but in women 
aged ≥35 years the median MOM for f -hCG increased and the median MOM for 
PAPP-A decreasing as gestation progressed. 
 The DR of the serum markers was 66.5 percent. In women <35 years, the serum 
markers gave a DR of only 38.6 percent, whereas in women of ≥35 years, the 
biochemistry detected 82.7 percent of DS pregnancies (p<0.01). The number of 
invasive procedures needed to detect one case of DS was thus 19 in women <35 
years, and 11 in women aged ≥35 years. When the FPR in both age groups was set at 
five percent, the DR in women aged <35 years increased to 68.2 percent, and in 
women aged ≥35 years it decreased to 71.9 percent. This clearly shows that the 
number of invasive procedures needed to detect one case of Down's syndrome was 
clearly higher in younger than in older age groups; 39 in younger women vs. 5 in 
older women. Biochemical marker data for women in the different age groups 
considered are presented in Table 6. 
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 In the entire screened population, the median gestational age was week 11+0. 
Therefore, this gestational group was used as a reference group for statistical 
evaluation. For the reference group of 11 weeks, the median MOM of f -hCG was 
0.99, and the median MOM of PAPP-A was 0.99. The median f -hCG MOM was 
0.99–1.06 during pregnancy weeks 8–13, but the median MOM of PAPP-A showed a 
greater variance depending on the stage of gestation, being <0.70 during pregnancy 
weeks 8–9, and >0.93 from week 10 onwards.  The highest DR for the biochemical 
markers was achieved at the end of gestational week 9 (96.2 percent), while the 
lowest detection rate was found at the end of week 11 (56.5 percent) (p<0.01). The 
median maternal age was 38 years for both groups. When the FPR  in each age group 
was set at five percent, the DR was still highest in week 9 (88.5 percent) but lowest in 
week 8 (58.3 percent).  However, when using this fixed five percent cut-off, the 
number of invasive procedures needed to detect one case of Down's syndrome was 
highest in week 10 and lowest in weeks 8 and 13 (22 vs. 9). The median MOMs and 
DRs for selected gestational weeks are presented in Table 7. 
 
Table 7. Median MOMs and detection rates in the screened population (N=76949), and 
the Down's syndrome pregnancies (N=221), in selected gestational weeks compared to 
gestational week 11. 
Completed 
weeks 
 
8 
 
P 
 
9 
 
P 
 
10 
 
P 
 
11 
 
12 
 
P 
 
13 
 
P 
The screened population 
Median age 29 29 29 29 30 31 
N 2013 7906 17048 25440 21662 2880 
Median f -
hCG MOM 
 
1.03 
 
0.47 
 
1.06 
 
<0.01 
 
1.00 
 
0.55 
 
0.99 
 
1.02 
 
<0.01 
 
1.03 
 
0.03 
Median 
PAPP-A 
MOM 
 
 
0.48 
 
 
<0.01 
 
 
0.68 
 
 
<0.01 
 
 
0.95 
 
 
<0.01 
 
 
0.99 
 
 
0.96 
 
 
<0.01 
 
 
0.93 
 
 
<0.01 
FPR (%) 11.0 <0.01 8.9 <0.01 3.8 0.35 4.0 3.6 0.06 5.5 0.03 
The Down's syndrome pregnancies 
Median age 37 38 35 38 37 32 
N 12 26 40 62 65 16 
Median f -
hCG MOM 
 
1.91 
 
0.81 
 
1.69 
 
0.71 
 
1.42 
 
0.44 
 
1.56 
 
1.60 
 
0.92 
 
1.57 
 
0.41 
Median 
PAPP-A 
MOM 
 
 
0.27 
 
 
0.13 
 
 
0.20 
 
 
<0.01 
 
 
0.32 
 
 
0.03 
 
 
0.49 
 
 
0.47 
 
 
0.84 
 
 
0.44 
 
 
0.59 
DR (%) 75.0 0.34 96.2 <0.01 67.5 0.26 56.5 63.1 0.45 64.7 0.54 
DR at 5 % 
FPR  
 
58.3 
 
88.5 
 
72.5 
 
59.0 
 
65.6 
 
58.9 
NIPN 9 16 22 21 17 9 
NIPN = number of invasive tests needed to detect one T21 
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7 Discussion 
7.1 SUMMARY OF THE MAIN FINDINGS 
 
In study I, the combined FTS markers were compared between spontaneous 
pregnancies with different TTPs to those in IVF pregnancies. We found that a 
prolonged TTP is, at some level, associated with an increased FPR in the combined 
FTS. This raises a question of whether there is a need to adjust PAPP-A in the risk 
calculation for the waiting time to pregnancy. The observed difference in PAPP-A 
concentration is likely to have contributed in concert with maternal age to the 
calculation of DS risk, and further studies are needed before considering adjustments 
in the risk calculations for TTP, as well as for maternal age. 
 In study II, we investigated the profile of the biochemical markers in adverse 
pregnancy outcomes, including PA, in chromosomally normal pregnancies. The 
mechanism involved with the most adverse outcomes such as PD, PE, and SGA may 
be related to reduction in the protease activity of PAPP-A which affects the 
concentration of free IGF in early pregnancy. Low f -hCG and PAPP-A levels predict 
placental diseases – PE, PD, and SGA –, but not decidual diseases such as PA. 
 In studies III–IV, the DRs and the numbers of invasive procedures needed to 
detect one DS pregnancy in women between 15 and 48 years of age were examined 
according to 5-year age groupings. In addition, the performance of the first trimester 
biochemical screening markers at different maternal ages was analysed. The results 
reminded that it is absolutely crucial for all women participating in the prenatal 
screening program to be informed of the shortcomings of the available screening 
methods with regard to the maternal age. F -hCG and PAPP-A are of limited utility 
for detecting DS pregnancies in women under the age of 35, who represent the 
majority of pregnant women. Therefore, in young women, combined screening 
should be the method of choice. Since there was considerable variation in the levels 
of the biochemical markers, and especially PAPP-A, between the different age 
groups examined, we suggest that further research should focus on determining 
whether there is a need to introduce age-related MOMs in DS screening. 
 
7.2 THE VALIDITY OF THE RESULTS 
 
The key aim of the work described in this doctoral thesis was to examine the quality 
of the combined FTS. The study data was gathered using a routine screening method 
and therefore, the screened population provided an accurate representation of the 
entire pregnant population. More than 70 percent of pregnant women entered the 
combined FTS during the study period (Marttala et al. 2011, III). Extensive maternal 
information was gathered during pregnancy and the information was routinely 
registered with the maternity care units. The hospital-based registries of births and 
the national registers are reliable and extensive (Teperi 1993). The combined FTS was 
carried out under continuous monitoring during the pre-analytical, analytical, and 
post-analytical phases of blood sample collection. Invasive tests were performed by 
specialists, and the chromosome analyses were conducted at major accredited 
laboratories. In addition, internal and external quality controls were used in the risk 
calculation program and the laboratory methods for the biochemical markers in the 
combined FTS. All these factors suggest that the results for the normal screened 
population are valid. However, the incidence of DS pregnancies and adverse 
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pregnancy outcomes is probably underestimated, due to spontaneous abortion. 
Presumably not all DS pregnancies in the study population were found. The 
diagnoses of adverse outcomes, especially the recessive cases of PA, may be 
incomplete since these conditions have few symptoms. 
 The screening during pregnancy is much more extensive than mere DS screening. 
For instance, it involves collecting and verifying data influencing the pregnancy; 
twinning is diagnosed, the expected date of delivery is verified, and other 
chromosomal disorders are screened. These examinations rely on ultrasound scans 
that are properly performed. Unfortunately, when the screening data were collected, 
there were no regulations in Finland with regard to quality control or auditing of the 
NT or other first trimester ultrasonic measurements, and no training program was 
available to the midwives or gynaecologists performing the NT measurements. It is 
therefore possible that the NT measurements may have been mis-estimated, which 
would have influenced the observed DR values. The DRs and the data for the 
biochemical and the combined FTS are presented and compared to previously 
published results in Table 8. Some large studies, with a similar population size to 
ours, have reported higher DRs than found in the present study (Nicolaides et al. 
2005). This is probably a result of major centralising and adequate calibration of the 
MOMs, as well as ideal timing of blood sampling and the NT measurement (Wright 
et al. 2010). 
 
Table 8. The performance of screening and the incidence of invasive procedures using 
different FTS methods. 
 f -hCG and PAPP-A Combined FTS 
Study 
 
N Mean 
age 
(yrs) 
Incidence 
of DS (%) 
FPR 
(%) 
DR 
(%) 
NIPN FPR 
(%) 
DR 
(%) 
NIPN 
Malone et 
al. 2005 
 
36120 
 
27.1 
 
0.25 
    
5.0 
 
87 
 
23 
Wald et al. 
2003 
 
47053 
 
29 
 
0.21 
 
5.0 
 
83 
 
24 
 
5.0 
 
93 
 
23 
Marttala et 
al. 2011 
(III), Ranta 
et al. 2011 
(IV) 
 
 
 
 
76949 
 
 
 
 
29.3 
 
 
 
 
0.29 
 
 
 
 
4.1 
 
 
 
 
67 
 
 
 
 
18 
 
 
 
 
4.3 
 
 
 
 
82 
 
 
 
 
22 
Crossley et 
al. 2002 
 
17229 
 
29.9 
 
0.26 
 
5.0 
 
55 
 
37 
 
5.0 
 
82 
 
30 
Spencer et 
al. 2003  
 
12339 
 
30 
 
0.20 
    
5.2 
 
92 
 
35 
Nicolaides 
et al. 2005 
 
75821 
 
31 
 
0.43 
 
5.0 
 
67 
 
12 
 
5.0 
 
90 
 
13 
Krantz et 
al. 2000 
 
10251 
 
31.8 
 
0.49 
    
5.0 
 
91 
 
11 
Orlandi et 
al. 1997 
 
2010 
 
32 
 
0.55 
 
5.0 
 
61 
 
10 
 
5.0 
 
87 
 
10 
Bindra et 
al. 2002 
 
14383 
 
34 
 
0.57 
 
5.0 
 
60 
 
15 
 
5.0 
 
90 
 
10 
Wapner et 
al. 2003 
 
8514 
 
34 
 
0.72 
 
5.0 
 
67 
 
10 
 
5.0 
 
79 
 
9 
Kagan et 
al. 2009 
 
19736 
 
34.5 
 
0.62 
    
5.0 
 
93 
 
9 
 
In studies I II, there was a problem with the small size of the screened population, 
with the PA and IVF groups being particularly small. These results should be 
confirmed in a larger study. In addition, the reliability of the TTP data obtained in 
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study I could be questioned. TTP is anamnestic information, and is not solely 
dependent on the mother, but depending also on the factors associated with the male 
partner to the pregnant woman. 
 During the study, an error in the risk calculation was found in the median MOM 
of PAPP-A. In the entire screened population when the results of both Oulu and 
Kuopio University Hospital catchment areas were combined, the median MOM of 
PAPP-A was <1.00, indicating that the medians in the risk calculation programme 
calibration curve were not adequately fitted. Especially for women aged <25 years, 
who had the PAPP-A median MOM <0.90, the median MOMs of PAPP-A should be 
specified in following versions of the risk calculation programme, probably by 
collecting normal values from a larger population. The medians for this specific 
version of the risk calculation programme were collected from samples in a pregnant 
population at the mean maternal age of 29 years, and therefore this age group was 
over-presented. In addition, the distribution of external quality control samples 
represented a childbearing population with a similar age distribution. 
7.3 CLINICAL SIGNIFICANCE AND APPLICATION OF THE RESULTS 
The criteria for screening established by the WHO (WHO 1968) do not seem to be 
met completely in existing screens for DS or adverse pregnancy outcomes. DS and 
most adverse outcomes are not major health problems, and their incidence at the 
population level is low. Only PD has an incidence of more than five percent. There 
are no suitable tests with sufficient accuracy to screen for adverse outcomes in low-
risk populations. No established screening method exists to screen for most of the 
adverse pregnancy outcomes, including PA and PD. As the majority of adverse 
pregnancy outcomes are multifactorial, there is currently no evidence that routine 
screening for any of these conditions would significantly improve the outcome. In 
addition, no efficient intervention besides emphasized monitoring is available, and 
its benefits remain to be proven. Thus the costs of screening for adverse outcomes 
cannot be estimated. However, in addition to DS, there is a clinically recognizable 
stage during pregnancy for PE, and a suitable screening test for recognition, an 
agreement of whom to treat as patients (American Congress of Obstetricians and 
Gynecologists 2002), and case finding is a continuous process. Furthermore, clinical 
evidence-based intervention protocols are available (Bujold et al. 2009, WHO 2011). 
 Even though pregnancies with moderate or high risks for developing PD, PE or 
SGA can be recognized during the first trimester by their low concentrations of f -
hCG and PAPP-A, the incidence of PA appeared to be unpredictable on the basis of 
the combined FTS markers even in cases where patient and familial history both 
flagged up patients at risk. In addition, while the lower than normal concentrations 
of f -hCG and PAPP-A were statistically significant in PD, PE, and SGA pregnancies, 
the MOMs for f -hCG in each group still were within 10 percent of the normal 
values. Only the PAPP-A concentrations were ≥20 percent lower in pregnancies 
involving PE, PD and SGA, whereas in DS pregnancies the concentrations are 50 
percent lower. However, it seems that the way of thinking is changing in screening of 
adverse pregnancy outcomes and maternal risk factors should be recognised at the 
earliest possible stage (Nicolaides 2011). Changes in concentrations may have an 
effect on the results of screening, when maternal risk factors – amongst others 
smoking, very high maternal age, or TTP of over two years – are recognised during 
the first trimester (Nicolaides 2011). In adverse outcomes, if susceptibility for 
developing PE and SGA, perhaps PD, can be identified, more resources could be 
guided towards more efficient follow-up and health support in these women at risk. 
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If adverse outcomes are wanted screened, a new algorithm for this kind of risk 
assessment should to be designed. 
 Subfertile women, defined as those with TTP of two years or more, had 
significantly reduced serum PAPP-A concentrations in comparison to those showing 
normal fertility. Along with higher maternal age, the lower concentrations of PAPP-
A led to a higher FPR in DS screening. A high maternal age and a prolonged TTP 
were found to increase the risk of an adverse outcome. The risk calculation program 
does not factor in risks that may be presented by high maternal age, such as chronic 
diseases. Maternal age affects the median PAPP-A concentration but the MOMs are 
not age-adjusted – only the pregnancy-specific DS risk ratio is age-adjusted. More 
research into the effect of age on MOMs will be needed before any attempt at 
introducing such age adjustments.  
 The main difference between IVF women and those who took a long time to 
achieve a spontaneous pregnancy was the application of assisted reproduction 
techniques. Therefore, the lower than normal concentration of PAPP-A may also 
have affected the screening results for IVF pregnancies. FTS can equally well be 
applied to IVF pregnancies although the origin of the pregnancy should be noted.  
 Using a fixed FPR of five percent would increase the DR only in women over 24 
years of age, or only after gestational week 10. The most problematic age group in 
the screening proved to be women aged 25–29 years, who actually represented the 
most numerous group of the screened population. The manipulation of the cut-off 
level or FPR in the screening program would not lead to an improvement of the DR 
in young women, but possibly it would improve the DR in early first trimester 
screening. In the combined FTS, if both the biochemical markers and the NT scan are 
interpreted as normal in women aged ≥35 years, the number of invasive procedures 
could be reduced, as the majority of false negative screening results occur in women 
aged <35 years. If, however, a high NT indicates an elevated risk, the results of the 
biochemical screening are less important, especially in younger women. The effect of 
maternal and gestational ages should to be considered when examining the results of 
the combined FTS, both in euploid and aneuploid pregnancies. Patients should be 
counselled with regard to their age. In addition, the timing of the blood sampling at 
weeks 9–10 seems justified. 
 
7.4 FUTURE CONSIDERATIONS FOR THE COMBINED FIRST 
TRIMESTER SCREENING 
 
Methods of screening for DS during the first trimester are continuously under 
examination, worldwide. New markers are tested to assess their suitability for 
routine use; markers currently undergoing this process include ultrasonic venous 
duct flow changes (Matias et al. 1999) or the absence of the nasal bone (Cicero et al 
2001). The concentration of a disintegrin and metalloproteinase 12 (ADAM12) during 
the first trimester have been reported to be reduced in DS pregnancies (Laigaard et 
al. 2006, Valinen et al. 2009, Koster et al. 2011), and therefore ADAM12 has been 
suggested as a possible fourth first trimester screening marker.  Foetal DNA and 
especially the extent of its methylation, measured from the maternal serum, can be 
studied to diagnose DS non-invasively (Chim et al. 2008, Papageorgiou et al. 2011). If 
this was feasible, screening would naturally step aside as the diagnosis would be 
achieved at around the time that screening is performed at present.  
 To date, new markers reported in the academic literature have not yet entered into 
routine use and for the time being, the focus is on developing the quality of the 
combined FTS. The studies reported in this thesis have demonstrated that the 
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performance of combined FTS is reasonably good but it can be improved. This has 
been acknowledged by staff at the Eastern Finland Laboratory Centre and Kuopio 
University Hospital, which was one of the first Finnish institutions to offer the 
combined FTS in 2002. The risk calculation program is used routinely to calculate the 
risk ratio for trisomy 18, in addition to DS. The screening as a whole is well-audited. 
Quality control of the NT measurements is performed continuously: the personnel 
performing the measurements perform approximately 500 repetitions yearly, which 
is markedly more than the nationally recommended minimum, and a Performer-
specific follow-up in NT measurements has been in use since 2011 in the maternity 
clinic of Kuopio University Hospital. The study cannot compare the results in the 
performance of the NT measurements, but the quality control and training of the 
personnel involved in performing the NT measurements should lead to 
improvement in DRs for all age groups. In order to improve the utility of the 
combined FTS markers, the focus is on MOM-based assessment of the results and 
risk calculation. Centralising the NT measurements, the blood sample collection and 
their analyses, as well as risk calculation in major accredited laboratories also 
improves the quality of the combined FTS. Centralising means more repetitions to 
the health care personnel working with the combined FTS, constructing routines, and 
reducing the probability of mistakes. By centralizing the first trimester ultrasound 
scans, the measurement of CRL becomes more accurate and thus the estimation of 
NT more precise, which also improves the performance of the screening (Kagan et al. 
2012). 
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The Role of Biochemistry
Maternal and foetal characteristics 
affect the levels of the biochemical 
markers in first trimester Down’s 
syndrome screening. Pregnancy as-
sociated plasma protein A is not only 
the best marker to screen for Down’s 
syndrome, but also a significant 
marker for subfertility and adverse 
pregnancy outcomes, such as preterm 
delivery, preeclampsia and small for 
gestational age infants. In this the-
sis, the pregnancy associated plasma 
protein A was examined to elucidate 
how its concentration behaves in 
relation to maternal and gestational 
ages, as well as how these factors 
affect the detection rate of Down’s 
syndrome.   
